Substituted macrocyclic compounds, compositions containing the same, and uses thereof

By developing a novel deuterium-substituted macrocyclic compound, the drug resistance problem of EGFR del19/L858R T790M C797S mutation was solved, and effective targeted therapy of complex alleles and blood-brain barrier penetration were achieved, filling the existing ones Blanks of EGFR inhibitors in brain metastasis treatment.

CN115368378BActive Publication Date: 2024-11-19SHENZHEN TARGETRX INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210543580.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-05-21
Filing Date
2022-05-19
Publication Date
2024-11-19
Estimated Expiration
2042-05-19

AI Technical Summary

Technical Problem

Existing EGFR inhibitors are difficult to effectively inhibit the EGFR del19/L858R T790M C797S mutation, leading to drug resistance problems, and lacking the fourth-generation EGFR inhibitor that can penetrate the blood-brain barrier, making it unable to effectively treat brain metastases and complex tumor alleles Gene mutation.

Method used

A novel deuterium-substituted macrocyclic compound has been developed as a fourth-generation EGFR inhibitor, with extensive activity against EGFR del19/L858R variants, which can effectively inhibit T790M and C797S mutations, and has good metabolic stability and blood-brain Barrier permeability.

Benefits of technology

This compound ensures targeted therapy capabilities for complex alleles, extends patient response duration, reduces drug resistance, and can effectively penetrate the brain, solving the shortcomings of existing EGFR inhibitors in brain metastasis treatment .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115368378B_ABST
    Figure CN115368378B_ABST
Patent Text Reader

Abstract

The present invention provides a substituted macrocyclic compound and a composition comprising the compound and its use. The substituted macrocyclic compound is a compound represented by formula (I) or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvent compound. The compound of formula (I) can be used as a fourth-generation non-covalent EGFR tyrosine kinase inhibitor, which can inhibit complex EGFR mutations including T790M and / or C797S, while retaining activity against wild-type EGFR, and has high selectivity and good DMPK properties. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular, relates to a substituted macrocyclic compound and a composition comprising the compound and its use. More specifically, the present invention relates to certain deuterium-substituted (E)-1 1 ,2 6 ,7-Trimethyl-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3 -Dihydro-1 1 H,5 1 Compounds of H-11-oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-3-one and its derivatives and their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates. These deuterium-substituted compounds and their compositions can be used as fourth-generation non-covalent EGFR tyrosine kinase inhibitors, capable of inhibiting complex EGFR mutations including T790M and / or C797S, while retaining activity against EGFR WT, with high selectivity and good DMPK properties. Background Art

[0002] Epidermal Growth Factor Receptor (EGFR) is a receptor tyrosine kinase that transduces mitogenic signals. In adenocarcinoma histology, EGFR gene mutations are found in approximately 12% to 47% of non-small cell lung cancer (NSCLC) tumors. The two most common EGFR mutations found in NSCLC tumors are EGFR deletion of amino acids 746 to 750 in the exon 19 region (del 19 mutation) and EGFR mutation of amino acid 858 from leucine to arginine in the exon 21 region (L858R mutation). These two mutations cause ligand-independent EGFR activation and are collectively referred to as EGFR M+ The del 19 and L858R mutations in EGFR sensitize NSCLC tumors to treatment with EGFR tyrosine kinase inhibitors (TKIs). Clinical experience has shown that EGFR is resistant to first-line treatment with the first-, second-, and third-generation EGFR inhibitors erlotinib, gefitinib, afatinib, and osimertinib. M+ The objective response rate for patients with NSCLC is approximately 60-85%. These responses suggest that EGFR M+NSCLC cells and tumors rely on oncogenic EGFR activity for survival and proliferation, establishing del19 or L858R mutated EGFR as an effective drug target and predictive biomarker for the treatment of NSCLC.

[0003] Although patients' tumor responses are accompanied by significant tumor shrinkage, responses are usually not durable, and most patients relapse within 10 to 12 months after treatment with first- and second-generation EGFR inhibitors. The most important molecular mechanism underlying progression is that 50% to 70% of patients treated with first- and second-generation EGFR inhibitors acquire a second-level EGFR mutation, T790M. This mutation weakens the inhibitory activity of first- and second-generation inhibitors in cell-based assays.

[0004] Mutation-selective and covalent third-generation EGFR inhibitors, such as osimertinib, have been developed, which can effectively inhibit EGFR first-class mutations del19 and L858R with and without the second-class T790M resistance mutation. M+ Efficacy in the second-line treatment of T790M-positive NSCLC has been clinically demonstrated to be dependent on the mutated EGFR allele for tumor cell survival and proliferation. M+ Approximately 70% of T790M-positive patients respond to second-line osimertinib treatment. However, disease progression occurs after an average duration of 10 months. Potential mechanisms of acquired resistance to third-generation EGFR inhibitors have been studied in a small number of patients and have begun to emerge. Existing clinical data suggest that a major resistance mechanism is the acquisition of a third-level mutation of EGFR, C797S, in approximately 20-40% of second-line patients who relapse on osimertinib. Third-generation EGFR inhibitors (e.g., osimertinib) are covalently linked to EGFR via residue C797. In cell models, the C797S mutation eliminates the activity of the third-generation EGFR inhibitors tested. In second-line patients, the C797S mutation is found in conjunction with the EGFR del19 genotype and is located on the same allele as the T790M mutation (cis configuration) (accounting for 82% of C797S+ patients). Crucially, the EGFR del19 / L858R T790M C797S cis-mutant kinase variant that arises in second-line patients who progress on osimertinib is no longer inhibited by first-, second-, or third-generation EGFR inhibitors. Based on the fact that the C797S mutation was detected at progression on osimertinib, tumor cell survival and proliferation in EGFR del19 / L858R T790M C797S patients may be dependent on this mutant allele and could be inhibited by targeting this allele. M+Other EGFR resistance mutations with lower rates than C797S were also found in second-line NSCLC patients: L718Q, L792F / H / Y, and C797G / N.

[0005] Osimertinib is also approved for the treatment of previously untreated EGFR M+ In patients with NSCLC, disease progression occurs after a median disease duration of 19 months. Although the spectrum of EGFR resistance mutations after first-line osimertinib treatment has not been extensively studied, the first available data suggest that the C797S mutation, which abrogates osimertinib activity, also emerges.

[0006] The fact that there are no approved EGFR inhibitors that inhibit EGFR del19 / L858R T790M C797S mutations highlights the medical need for next-generation EGFR inhibitors (fourth-generation EGFR inhibitors). Fourth-generation EGFR TKIs should effectively inhibit EGFR del19 and / or L858R regardless of the presence of two common resistance mutations, T790M and C797S. The utility of this fourth-generation EGFR inhibitor will be enhanced by the activity of the compound against additional resistance mutations, such as the potential osimertinib-resistant mutations C797X (X = S, G, N) and L792F / H / Y. The broad activity of the molecule against EGFR del19 / L858R variants that do not yet have T790M and / or C797S mutations will ensure that the new compound can effectively address the expected allelic complexity in patient tumors as a monotherapy. At the same time, to facilitate effective dosing and reduce off-target toxicity of the compounds, another ideal property of the fourth-generation EGFR inhibitors is the ability to effectively penetrate into the brain (blood-brain barrier penetration) so as to be able to treat brain metastases and leptomeningeal disease. Finally, compared with existing EGFR inhibitors, the fourth-generation EGFR inhibitors have reduced drug resistance to increase the duration of response in patients.

[0007] The above-mentioned properties of the fourth-generation EGFR inhibitors will allow the treatment of patients who have progressed after second-line treatment with third-generation inhibitors, who currently have no targeted treatment options. In addition, these properties may also enable the fourth-generation EGFR inhibitors to provide a longer duration of response in patients with earlier lines of treatment (e.g., patients who have progressed on first-line osimertinib treatment with EGFR C797S mutations and first-line patients). The activity of the fourth-generation EGFR inhibitors against resistance mutations such as T790M, C797X (X = S, G, N), and L792X (X = F, H, Y) may delay the development of resistance through EGFR on-target mutations in NSCLC tumors. The properties outlined above define the fourth-generation EGFR inhibitor as the first EGFR inhibitor that can effectively target NSCLC tumor patients carrying EGFRdel19 / L858R T790M C797X / L792X variants. Furthermore, the fourth generation of EGFR inhibitors will be the first C797X-active compounds that also inhibit the T790M-positive allele, have EGFR wild-type-retaining activity and potently penetrate into the brain.

[0008] BI-4020 (chemical name is (R,E)-1 1 ,2 6 ,7-Trimethyl-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3 -Dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-3-one (having the following structural formula) is a fourth-generation, orally active, non-covalent EGFR tyrosine kinase inhibitor developed by Boehringer Ingelheim Pharmaceuticals. Protein and cell experiments have shown that it can effectively inhibit T790M and / or C797S mutated EGFR, while retaining activity against wild-type EGFR.

[0009]

[0010] Poor absorption, distribution, metabolism and / or excretion (ADME) properties are known to be the main reason for the failure of many candidate drugs in clinical trials. Many drugs currently on the market also limit their scope of application due to poor ADME properties. Rapid drug metabolism will cause many drugs that could have been highly effective in treating diseases to be difficult to make into medicines due to excessively rapid metabolism and clearance from the body. Although frequent or high-dose medication may solve the problem of rapid drug clearance, this method will bring about problems such as poor patient compliance, side effects caused by high-dose medication, and rising treatment costs. In addition, rapidly metabolized drugs may also expose patients to adverse toxic or reactive metabolites.

[0011] It is still a challenging task to find novel and effective fourth-generation EGFR inhibitors with good oral bioavailability and drugability. Therefore, the art still needs to develop compounds suitable for fourth-generation EGFR inhibitors with selective inhibitory activity and / or better pharmacodynamics / pharmacokinetics, and the present invention provides such compounds. Summary of the invention

[0012] In view of the above technical problems, the present invention discloses a novel deuterium-substituted macrocyclic compound as an effective fourth-generation EGFR inhibitor, which exhibits a wide range of activity against EGFR del 19 / L858R variants with or without T790M and / or C797S mutations, which ensures that the compounds of the present invention can effectively cope with the expected allele complexity in patient tumors as a monotherapy. In order to promote effective dose administration and reduce EGFR-mediated on-target toxicity, the compounds of the present invention have a reduced inhibitory potential for wild-type EGFR and show higher selectivity in the entire human kinase group. Another characteristic of the compounds of the present invention is the potential ability to penetrate into the brain (blood-brain barrier penetration) so as to be used to treat brain metastases and leptomeningeal diseases. In addition to the inhibitory effect and efficacy, the compounds of the present invention also show good solubility and better metabolic stability and / or pharmacokinetic properties.

[0013] To this end, the present invention adopts the following technical solutions:

[0014] The first aspect of the present invention provides a compound of formula (I):

[0015]

[0016] in,

[0017] Y1, Y2, Y3, Y4, Y5 and Y6 are each independently selected from hydrogen, deuterium or halogen;

[0018] R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0019] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0020] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0021] Provided that the above compound contains at least one deuterium atom;

[0022] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0023] On the other hand, the present invention provides a pharmaceutical composition containing a compound of the present invention or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvent compound and a pharmaceutically acceptable excipient. In a specific embodiment, the compound of the present invention is provided in the pharmaceutical composition in an effective amount. In a specific embodiment, the compound of the present invention is provided in a therapeutically effective amount. In a specific embodiment, the compound of the present invention is provided in a preventive effective amount. In a specific embodiment, the pharmaceutical composition also includes another therapeutic agent.

[0024] On the other hand, the present invention provides a method for preparing the pharmaceutical composition as described above, comprising the following steps: mixing a pharmaceutically acceptable excipient with the compound of the present invention or its tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate to form a pharmaceutical composition.

[0025] In another aspect, the present invention provides the use of a compound of the present invention or its tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate, or the above-mentioned pharmaceutical composition in the preparation of a medicament for treating and / or preventing diseases associated with or mediated by mutant EGFR.

[0026] On the other hand, the present invention further provides a method for treating and / or preventing diseases associated with or mediated by mutant EGFR, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention or its tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate, or a pharmaceutical composition of the present invention.

[0027] In a specific embodiment, the mutant EGFR is selected from EGFR del19, EGFR L858R, EGFR del19T790M, EGFR L858R T790M, EGFR del19 T790M C797X (X=S, G, N), EGFR L858R T790MC797X (X=S, G, N), EGFR del19 T790M L792X (X=F, H, Y) or EGFR L858R T790M L792X (X=F, H, Y); preferably, the mutant EGFR is selected from EGFR del19, EGFR L858R, EGFR del19 T790M, EGFRL858R T790M, EGFR del19 T790M C797S or EGFR L858R T790M C797S.

[0028] In a specific embodiment, the disease associated with or mediated by the mutant EGFR is cancer; preferably, the cancer is selected from lung cancer, brain cancer, colorectal cancer, bladder cancer, urothelial carcinoma, breast cancer, prostate cancer, ovarian cancer, head and neck cancer, pancreatic cancer, gastric cancer, mesothelioma, and metastases thereof (especially brain metastases); preferably, lung cancer is selected from non-small cell lung cancer, including locally advanced or metastatic NSCLC, NSCLC adenocarcinoma, NSCLC with squamous histology and NSCLC with non-squamous histology; more preferably, lung cancer is NSCLC adenocarcinoma.

[0029] Other objects and advantages of the present invention will be apparent to those skilled in the art from the following detailed description, examples and claims.

[0030] definition

[0031] Herein, unless otherwise specified, "deuterated" means that one or more hydrogen atoms in a compound or group are replaced by deuterium; deuterated can be monosubstituted, disubstituted, polysubstituted or fully substituted. The term "one or more deuterated" and "one or more deuterated" can be used interchangeably.

[0032] As used herein, unless otherwise specified, a "non-deuterated compound" refers to a compound containing deuterium atoms at a ratio not higher than the natural deuterium isotope content (0.015%).

[0033] As used herein, the term "subject" includes, but is not limited to, humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or older adults)) and / or non-human animals, e.g., mammals, e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In some embodiments, the subject is a human. In other embodiments, the subject is a non-human animal.

[0034] "Disease," "disorder," and "condition" are used interchangeably herein.

[0035] As used herein, and unless otherwise indicated, the terms "treat," "treatment," "treating ...

[0036] Generally, an "effective amount" of a compound refers to an amount sufficient to cause a target biological response. As will be appreciated by those of ordinary skill in the art, the effective amount of the compounds of the invention may vary depending on factors such as the biological target, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and symptoms of the subject. An effective amount includes both therapeutic and prophylactic treatment effective amounts.

[0037] Unless otherwise specified, a "therapeutically effective amount" of a compound as used herein is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, or to delay or minimize one or more symptoms associated with the disease, disorder, or condition. A therapeutically effective amount of a compound refers to an amount of a therapeutic agent, used alone or in combination with other therapies, that provides a therapeutic benefit in the treatment of a disease, disorder, or condition. The term "therapeutically effective amount" may include an amount that improves overall treatment, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of other therapeutic agents.

[0038] Unless otherwise specified, a "prophylactically effective amount" of a compound as used herein is an amount sufficient to prevent a disease, disorder, or condition, or an amount sufficient to prevent one or more symptoms associated with a disease, disorder, or condition, or an amount to prevent the recurrence of a disease, disorder, or condition. A prophylactically effective amount of a compound refers to an amount of a therapeutic agent used alone or in combination with other agents that provides a prophylactic benefit in the process of preventing a disease, disorder, or condition. The term "prophylactically effective amount" may include an amount that improves overall prevention, or an amount that enhances the prophylactic efficacy of other prophylactic agents.

[0039] "Combination" and related terms refer to simultaneous or sequential administration of therapeutic agents of the invention. For example, a compound of the invention can be administered simultaneously or sequentially with another therapeutic agent in separate unit dosage forms, or simultaneously with another therapeutic agent in a single unit dosage form.

[0040] Abbreviations

[0041] Mes:Methylsulfonyl

[0042] Ts: p-Toluenesulfonyl

[0043] Boc: tert-butyloxycarbonyl

[0044] Cbz: benzyloxycarbonyl

[0045] Fmoc: fluorenylmethoxycarbonyl

[0046] Alloc: Allyloxycarbonyl

[0047] Teco: 2-(Trimethylsilyl)ethyl acetate

[0048] Bn: benzyl

[0049] SEM-Cl: 2-(Trimethylsilyl)ethoxymethyl chloride

[0050] NIS: N-iodosuccinimide

[0051] DBBPY: 4,4'-di-tert-butyl-2,2'-bipyridine

[0052] Pd2(dba)3: tris(dibenzylideneacetone)dipalladium

[0053] Dess-Martin periodinane: 1,1,1-tri(acetoxy)-1,1-dihydro-1,2-benzimidoyl-3-(1H)-one

[0054] NaBH(OAc)3: Sodium tri(acetoxy)borohydride

[0055] TBTU: O-(1H-benzotriazol-3-yl)-N,N,N',N'-tetramethylhexauronium tetrafluorophosphate

[0056] Cs2CO3: Cesium carbonate

[0057] K2CO3: Potassium carbonate

[0058] NaH: Sodium hydride

[0059] DIPEA: N,N-diisopropylethylamine

[0060] HCl: hydrochloric acid

[0061] Tol: Toluene

[0062] MTBE: Methyl tert-butyl ether

[0063] 1,4-dioxane: 1,4-dioxane

[0064] i-PrOH: isopropanol

[0065] EA: Ethyl acetate

[0066] THF: Tetrahydrofuran

[0067] DCM: dichloromethane

[0068] DMF: N,N-dimethylformamide DETAILED DESCRIPTION

[0069] Compound

[0070] As used herein, "compounds of the present invention" refers to compounds of the following formula (I)-(V) and subsets thereof (e.g., compounds of formula (IA), formula (IB)), or tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof.

[0071] In one embodiment, the present invention relates to compounds of formula (I):

[0072]

[0073] in,

[0074] Y1, Y2, Y3, Y4, Y5 and Y6 are each independently selected from hydrogen, deuterium or halogen;

[0075] R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0076] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0077] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0078] Provided that the above compound contains at least one deuterium atom;

[0079] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0080] In a specific embodiment, the deuterium isotope content of deuterium at the deuterated position is at least 0.015% greater than the natural deuterium isotope content, preferably greater than 30%, more preferably greater than 50%, more preferably greater than 75%, more preferably greater than 95%, and more preferably greater than 99%.

[0081] Specifically, in the present invention, Y1, Y2, Y3, Y4, Y5, Y6, R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 The deuterium isotope content at each deuterated position of X1, X2, X3 and X4 is at least greater than the natural isotope content by 0.015%, preferably greater than 1%, more preferably greater than 5%, more preferably greater than 10%, more preferably greater than 15%, more preferably greater than 20%, more preferably greater than 25%, more preferably greater than 30%, more preferably greater than 35%, more preferably greater than 40%, more preferably greater than 45%, more preferably greater than 50%, more preferably greater than 55%, more preferably greater than 60%, more preferably greater than 65%, more preferably greater than 70%, more preferably greater than 75%, more preferably greater than 80%, more preferably greater than 85%, more preferably greater than 90%, more preferably greater than 95%, more preferably greater than 99%.

[0082] In another specific embodiment, the compound of the present invention contains at least one deuterium atom, preferably two deuterium atoms, more preferably three deuterium atoms, more preferably four deuterium atoms, more preferably five deuterium atoms, more preferably six deuterium atoms, more preferably seven deuterium atoms, more preferably eight deuterium atoms, more preferably nine deuterium atoms, more preferably ten deuterium atoms, more preferably eleven deuterium atoms, more preferably twelve deuterium atoms, more preferably thirteen deuterium atoms, more preferably fourteen deuterium atoms, more preferably fifteen deuterium atoms, more preferably sixteen deuterium atoms, more preferably seventeen deuterium atoms, more preferably eighteen deuterium atoms, more preferably nineteen deuterium atoms. More preferably, it contains twenty deuterium atoms, more preferably twenty-one deuterium atoms, more preferably twenty-two deuterium atoms, more preferably twenty-three deuterium atoms, more preferably twenty-four deuterium atoms, more preferably twenty-five deuterium atoms, more preferably twenty-six deuterium atoms, more preferably twenty-seven deuterium atoms, more preferably twenty-eight deuterium atoms, more preferably twenty-nine deuterium atoms, more preferably thirty deuterium atoms, more preferably thirty-one deuterium atoms, more preferably thirty-two deuterium atoms, more preferably thirty-three deuterium atoms, more preferably thirty-four deuterium atoms, more preferably thirty-five deuterium atoms, more preferably thirty-six deuterium atoms, and more preferably thirty-seven deuterium atoms.

[0083] In another specific embodiment, "Y1, Y2, Y3, Y4, Y5 and Y6 are each independently selected from hydrogen, deuterium or halogen" includes Y1 selected from hydrogen, deuterium or halogen, Y2 selected from hydrogen, deuterium or halogen, Y3 selected from hydrogen, deuterium or halogen, and so on, until Y6 is selected from hydrogen, deuterium or halogen. More specifically, it includes Y1 is hydrogen, Y1 is deuterium or Y1 is halogen (F, Cl, Br or I), Y2 is hydrogen, Y2 is deuterium or Y2 is halogen (F, Cl, Br or I), Y3 is hydrogen, Y3 is deuterium or Y3 is halogen (F, Cl, Br or I), and so on, until Y6 is hydrogen, Y6 is deuterium or Y6 is halogen (F, Cl, Br or I).

[0084] In another specific embodiment, "R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 "are each independently selected from hydrogen or deuterium" includes R1 selected from hydrogen or deuterium, R2 selected from hydrogen or deuterium, R3 selected from hydrogen or deuterium, and so on, until R 19More specifically, R1 is hydrogen or R1 is deuterium, R2 is hydrogen or R2 is deuterium, R3 is hydrogen or R3 is deuterium, and so on, R 19 is hydrogen or R 19 It is the technical solution of deuterium.

[0085] In another specific embodiment, "X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D" includes the technical scheme that X1 is selected from CH3, CD3, CHD2 or CH2D, X2 is selected from CH3, CD3, CHD2 or CH2D, and X3 is selected from CH3, CD3, CHD2 or CH2D. More specifically, it includes the technical scheme that X1 is CH3, X1 is CD3, X1 is CHD2 or X1 is CH2D, X2 is CH3, X2 is CD3, X2 is CHD2 or X2 is CH2D, and X3 is CH3, X3 is CD3, X3 is CHD2 or X3 is CH2D.

[0086] In another specific embodiment, "X4 is selected from H, CH3, CD3, CHD2 or CH2D" includes the technical solutions that X4 is H, X4 is CH3, X4 is CD3, X4 is CHD2 or X4 is CH2D

[0087] In another embodiment, the present invention is directed to compounds of formula (IA):

[0088]

[0089] in,

[0090] Y1, Y2, Y3, Y4, Y5 and Y6 are each independently selected from hydrogen, deuterium or halogen;

[0091] R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0092] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0093] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0094] Provided that the above compound contains at least one deuterium atom;

[0095] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0096] In another embodiment, the present invention is directed to compounds of formula (IB):

[0097]

[0098] in,

[0099] Y1, Y2, Y3, Y4, Y5 and Y6 are each independently selected from hydrogen, deuterium or halogen;

[0100] R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0101] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0102] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0103] Provided that the above compound contains at least one deuterium atom;

[0104] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0105] In some embodiments of general formula (I), formula (IA) and formula (IB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 is CD3, Y1, Y2, Y3, Y4, Y5, Y6, R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2, X3 and X4 are as defined above.

[0106] In some embodiments of general formula (I), formula (IA) and formula (IB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 is CD3, Y1, Y2, Y3, Y4, Y5, Y6, R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X3 and X4 are as defined above.

[0107] In some embodiments of general formula (I), formula (IA) and formula (IB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 is CD3, Y1, Y2, Y3, Y4, Y5, Y6, R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2 and X4 are as defined above.

[0108] In some embodiments of general formula (I), formula (IA) and formula (IB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X4 is CD3, Y1, Y2, Y3, Y4, Y5, Y6, R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2 and X3 are as defined above.

[0109] In another embodiment, the present invention relates to compounds of formula (II):

[0110]

[0111] Among them, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0112] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0113] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0114] Provided that the above compound contains at least one deuterium atom;

[0115] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0116] In another embodiment, the present invention is directed to compounds of formula (IIA):

[0117]

[0118] Among them, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0119] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0120] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0121] Provided that the above compound contains at least one deuterium atom;

[0122] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0123] In another embodiment, the present invention is directed to compounds of formula (IIB):

[0124]

[0125] Among them, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0126] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0127] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0128] Provided that the above compound contains at least one deuterium atom;

[0129] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0130] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 is CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2, X3 and X4 are as defined above.

[0131] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 is CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R18 , R 19 , X1, X3 and X4 are as defined above.

[0132] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 is CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2 and X4 are as defined above.

[0133] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X4 is CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2 and X3 are as defined above.

[0134] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2, X3 and X4 are as defined above.

[0135] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X1, X2, X3 and X4 are as defined above.

[0136] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X2 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X3 and X4 are as defined above.

[0137] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X3 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2 and X4 are as defined above.

[0138] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X4 are CD3, R 10 , R 11 , R 12 , R13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2 and X3 are as defined above.

[0139] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 is CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2, X3 and X4 are as defined above.

[0140] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 is CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X2, X3 and X4 are as defined above.

[0141] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 and X3 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1 and X4 are as defined above.

[0142] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 and X4 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1 and X3 are as defined above.

[0143] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 is CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X3 and X4 are as defined above.

[0144] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 is CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X1, X3 and X4 are as defined above.

[0145] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 and X4 are CD3, R 10 , R 11 , R 12 , R13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1 and X2 are as defined above.

[0146] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 is CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2 and X4 are as defined above.

[0147] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 is CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X1, X2 and X4 are as defined above.

[0148] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X4 is CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2 and X3 are as defined above.

[0149] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X4 is CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X1, X2 and X3 are as defined above.

[0150] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, and X1, X2, X3 and X4 are as defined above.

[0151] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1, X2 and X3 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and X4 are as defined above.

[0152] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1, X2 and X4 are CD3, R 10 , R 11 , R 12 , R13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and X3 are as defined above.

[0153] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X2 are CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X3 and X4 are as defined above.

[0154] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X2 are CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X3 and X4 are as defined above.

[0155] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1, X3 and X4 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and X2 are as defined above.

[0156] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X3 are CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2 and X4 are as defined above.

[0157] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X3 are CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 is deuterium, R 10 , R 11 , X2 and X4 are as defined above.

[0158] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X4 are CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2 and X3 are as defined above.

[0159] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X4 are CD3, R 12 , R 13 , R 14 , R15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X2 and X3 are as defined above.

[0160] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2, X3 and X4 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and X 14 As defined above.

[0161] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 and X3 are CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1 and X4 are as defined above.

[0162] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 and X3 are CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X1 and X4 are as defined above.

[0163] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 and X4 are CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1 and X2 are as defined above.

[0164] In some embodiments of general formula (II), formula (IIA) and formula (IIB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 and X4 are CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X1 and X2 are as defined above.

[0165] In another embodiment, the present invention relates to compounds of formula (III):

[0166]

[0167] in,

[0168] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0169] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0170] Provided that the above compound contains at least one deuterium atom;

[0171] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0172] In another embodiment, the present invention is directed to compounds of formula (IIIA):

[0173]

[0174]

[0175] in,

[0176] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0177] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0178] Provided that the above compound contains at least one deuterium atom;

[0179] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0180] In another embodiment, the present invention is directed to compounds of formula (IIIB):

[0181]

[0182] in,

[0183] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0184] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0185] Provided that the above compound contains at least one deuterium atom;

[0186] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0187] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1 is CD3, and X2, X3 and X4 are as defined above.

[0188] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X2 is CD3, and X1, X3 and X4 are as defined above.

[0189] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X3 is CD3, and X1, X2 and X4 are as defined above.

[0190] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X4 is CD3, and X1, X2 and X3 are as defined above.

[0191] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1 and X2 are CD3, and X3 and X4 are as defined above.

[0192] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1 and X3 are CD3, and X2 and X4 are as defined above.

[0193] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1 and X4 are CD3, and X2 and X3 are as defined above.

[0194] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X2 and X3 are CD3, and X1 and X4 are as defined above.

[0195] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X2 and X4 are CD3, and X1 and X3 are as defined above.

[0196] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1, X2 and X3 are CD3, and X4 is as defined above.

[0197] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1, X2 and X4 are CD3, and X3 is as defined above.

[0198] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1, X3 and X4 are CD3, and X2 is as defined above.

[0199] In some embodiments of general formula (III), formula (IIIA) and formula (IIIB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X2, X3 and X4 are CD3, and X1 is as defined above.

[0200] In another embodiment, the present invention is directed to compounds of formula (IV):

[0201]

[0202] in,

[0203] R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0204] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0205] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0206] Provided that the above compound contains at least one deuterium atom;

[0207] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0208] In another embodiment, the present invention is directed to compounds of formula (IVA):

[0209]

[0210] R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0211] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0212] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0213] Provided that the above compound contains at least one deuterium atom;

[0214] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0215] In another embodiment, the present invention is directed to compounds of formula (IVB):

[0216]

[0217] R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0218] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0219] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0220] Provided that the above compound contains at least one deuterium atom;

[0221] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0222] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 is CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2, X3 and X4 are as defined above.

[0223] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 is CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X3 and X4 are as defined above.

[0224] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 is CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2 and X4 are as defined above.

[0225] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X4 is CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2 and X3 are as defined above.

[0226] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2, X3 and X4 are as defined above.

[0227] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X1, X2, X3 and X4 are as defined above.

[0228] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X2 are CD3, R 10 , R 11 , R 12 , R 13, R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X3 and X4 are as defined above.

[0229] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X3 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2 and X4 are as defined above.

[0230] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X4 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2 and X3 are as defined above.

[0231] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 is CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2, X3 and X4 are as defined above.

[0232] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 is CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X2, X3 and X4 are as defined above.

[0233] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 and X3 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1 and X4 are as defined above.

[0234] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 and X4 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1 and X3 are as defined above.

[0235] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 is CD3, R 10 and R 11 is deuterium, R 12 , R13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X3 and X4 are as defined above.

[0236] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 is CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X1, X3 and X4 are as defined above.

[0237] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 and X4 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1 and X2 are as defined above.

[0238] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 is CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2 and X4 are as defined above.

[0239] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 is CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X1, X2 and X4 are as defined above.

[0240] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X4 is CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2 and X3 are as defined above.

[0241] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X4 is CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X1, X2 and X3 are as defined above.

[0242] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein R 10 , R 11 , R 12 , R 13, R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, and X1, X2, X3 and X4 are as defined above.

[0243] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1, X2 and X3 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and X4 are as defined above.

[0244] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1, X2 and X4 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and X3 are as defined above.

[0245] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X2 are CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X3 and X4 are as defined above.

[0246] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X2 are CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X3 and X4 are as defined above.

[0247] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1, X3 and X4 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and X2 are as defined above.

[0248] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X3 are CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2 and X4 are as defined above.

[0249] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X3 are CD3, R 12 , R 13 , R 14 , R15 , R 16 , R 17 , R 18 , R 19 is deuterium, R 10 , R 11 , X2 and X4 are as defined above.

[0250] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X4 are CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X2 and X3 are as defined above.

[0251] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X1 and X4 are CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X2 and X3 are as defined above.

[0252] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2, X3 and X4 are CD3, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and X1 are as defined above.

[0253] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 and X3 are CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1 and X4 are as defined above.

[0254] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X2 and X3 are CD3, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X1 and X4 are as defined above.

[0255] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 and X4 are CD3, R 10 and R 11 is deuterium, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1 and X2 are as defined above.

[0256] In some embodiments of general formula (IV), formula (IVA) and formula (IVB), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X3 and X4 are CD3, R 12 , R 13 , R 14 , R15 , R 16 , R 17 , R 18 and R 19 is deuterium, R 10 , R 11 , X1 and X2 are as defined above.

[0257] In another embodiment, the present invention is directed to compounds of formula (V):

[0258]

[0259] in,

[0260] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0261] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0262] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0263] In another embodiment, the present invention is directed to compounds of formula (VA):

[0264]

[0265] in,

[0266] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0267] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0268] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0269] In another embodiment, the present invention is directed to compounds of formula (VB):

[0270]

[0271] in,

[0272] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0273] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0274] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0275] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1 is CD3, and X2, X3 and X4 are as defined above.

[0276] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X2 is CD3, and X1, X3 and X4 are as defined above.

[0277] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X3 is CD3, and X1, X2 and X4 are as defined above.

[0278] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X4 is CD3, and X1, X2 and X3 are as defined above.

[0279] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1 and X2 are CD3, and X3 and X4 are as defined above.

[0280] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1 and X3 are CD3, and X2 and X4 are as defined above.

[0281] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1 and X4 are CD3, and X2 and X3 are as defined above.

[0282] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X2 and X3 are CD3, and X1 and X4 are as defined above.

[0283] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X2 and X4 are CD3, and X1 and X3 are as defined above.

[0284] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1, X2 and X3 are CD3, and X4 is as defined above.

[0285] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1, X2 and X4 are CD3, and X3 is as defined above.

[0286] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X1, X3 and X4 are CD3, and X2 is as defined above.

[0287] In some embodiments of general formula (V), formula (VA) and formula (VB), preferably, the present invention relates to the above-mentioned compounds, or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein X2, X3 and X4 are CD3, and X1 is as defined above.

[0288] As a preferred embodiment of the present invention, the compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, is selected from any of the following compounds:

[0289]

[0290]

[0291]

[0292]

[0293]

[0294]

[0295]

[0296]

[0297]

[0298]

[0299]

[0300]

[0301] The compounds of the present invention may include one or more asymmetric centers and may therefore exist in a variety of stereoisomeric forms, for example, enantiomers and / or diastereoisomeric forms. For example, the compounds of the present invention may be individual enantiomers, diastereomers or geometric isomers (e.g., cis and trans isomers), or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis.

[0302] Those skilled in the art will appreciate that organic compounds can form complexes with solvents in which they react or from which they precipitate or crystallize. These complexes are referred to as "solvates". When the solvent is water, the complex is referred to as a "hydrate". The present invention encompasses all solvates of the compounds of the present invention.

[0303] The term "solvate" refers to a form of a compound or its salt that is combined with a solvent, usually formed by a solvent decomposition reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, ether, etc. The compounds described herein can be prepared, for example, in a crystalline form and can be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include stoichiometric solvates and non-stoichiometric solvates. In some cases, the solvate will be able to separate, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid. "Solvate" includes solvates in solution and separable solvates. Representative solvates include hydrates, ethanolates and methanolates.

[0304] The term "hydrate" refers to a compound that is combined with water. Generally, the ratio of the number of water molecules contained in the hydrate of a compound to the number of molecules of the compound in the hydrate is determined. Therefore, the hydrate of a compound can be represented by, for example, the general formula R·xH2O, where R is the compound, and x is a number greater than 0. A given compound can form more than one type of hydrate, including, for example, a monohydrate (x is 1), a lower hydrate (x is a number greater than 0 and less than 1, for example, a hemihydrate (R·0.5H2O)) and a polyhydrate (x is a number greater than 1, for example, a dihydrate (R·2H2O) and a hexahydrate (R·6H2O)).

[0305] The compounds of the present invention can be in amorphous or crystalline form (polymorph). In addition, the compounds of the present invention can exist in one or more crystalline forms. Therefore, the present invention includes all amorphous or crystalline forms of the compounds of the present invention within its scope. The term "polymorph" refers to the crystalline form (or its salt, hydrate or solvate) of a compound with a specific crystal packing arrangement. All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardnesses, crystal shapes, photoelectric properties, stability and solubility. Recrystallization solvents, crystallization rates, storage temperatures and other factors can lead to a dominant crystalline form. The various polymorphs of a compound can be prepared by crystallization under different conditions.

[0306] The present invention also includes isotopically labeled compounds which are identical to those of the present invention but for which one or more atoms have been replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Examples of isotopes that can be introduced into the present compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, e.g. 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. Compounds of the present invention containing the above isotopes and / or other isotopes of other atoms, their prodrugs and pharmaceutically acceptable salts of the compounds or prodrugs are within the scope of the present invention. Certain isotopically labeled compounds of the present invention, such as those in which a radioactive isotope (e.g. 3 H and 14 C) can be used for drug and / or substrate tissue distribution assays. 3H and carbon-14, i.e. 14 C isotopes are particularly preferred because they are easy to prepare and detect. 2 H, because higher metabolic stability can provide therapeutic benefits, such as prolonged half-life in vivo or reduced dosage requirements, and thus may be preferred in some cases. Isotope-labeled compounds of formula (I) of the present invention and their prodrugs can generally be prepared by replacing non-isotope-labeled reagents with readily available isotope-labeled reagents when carrying out the processes disclosed in the following schemes and / or Examples and Preparation Examples.

[0307] In addition, prodrugs are also included in the context of the present invention. The term "prodrug" as used herein refers to a compound that is converted into its active form having a medical effect in vivo by, for example, hydrolysis in the blood. Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the ACSSymposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and D. Fleisher, S. Ramon and H. Barbra "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19 (2) 115-130, each of which is incorporated herein by reference.

[0308] Prodrugs are any covalently bonded compounds of the present invention that release the parent compound in vivo when such prodrugs are administered to a patient. Prodrugs are usually prepared by modifying functional groups, and the modification is carried out in a manner that allows the modification to be cleaved to produce the parent compound by conventional manipulation or in vivo. Prodrugs include, for example, compounds of the present invention in which hydroxyl, amino or sulfhydryl groups are bonded to any group, which can be cleaved to form hydroxyl, amino or sulfhydryl groups when administered to a patient. Therefore, representative examples of prodrugs include, but are not limited to, acetate / amide, formate / amide and benzoate / amide derivatives of hydroxyl, sulfhydryl and amino functional groups of compounds of formula (I). In addition, in the case of carboxylic acid (-COOH), esters such as methyl esters, ethyl esters, etc. can be used. Esters themselves can be active and / or can be hydrolyzed under human body conditions. Suitable pharmaceutically acceptable in vivo hydrolyzable ester groups include those groups that are easily decomposed in the human body to release the parent acid or its salt.

[0309] Methods for preparing the compounds of the present invention

[0310] The compounds of the present invention (including salts thereof) can be prepared using known organic synthesis techniques and can be synthesized according to any of a variety of possible synthetic pathways (such as those in the scheme below). The reaction for preparing the compounds of the present invention can be carried out in a suitable solvent, and a technician in the field of organic synthesis can easily select a solvent. A suitable solvent can be substantially unreactive with a starting material (reactant), an intermediate or a product at a temperature for carrying out the reaction (e.g., a temperature within the range of the solvent freezing temperature to the solvent boiling temperature). A given reaction can be carried out in a solvent or a mixture of more than one solvent. A technician can select a solvent for a specific reaction step according to the specific reaction step.

[0311] The preparation of the compounds of the present invention may involve the protection and removal of different chemical groups. One skilled in the art can easily determine whether protection and removal of protection and the selection of appropriate protecting groups are required. The chemical properties of protecting groups can be found, for example, in Wuts and Greene, Protective Groups in Organic Synthesis, 4th Edition, John Wiley & Sons: New Jersey, (2006), which is incorporated herein by reference in its entirety.

[0312] The compounds of the present invention can be reacted with an optically active resolving agent to form a pair of diastereomeric compounds, separate diastereoisomers and recycle the enantiomers of optical purity to prepare their single stereoisomers. The diastereomeric derivatives of the compounds of the present invention can be used to carry out the separation of enantiomers, preferably dissociable complexes (e.g., crystalline diastereomeric salts). Diastereomers have significantly different physical properties (e.g., melting point, boiling point, solubility, reactivity, etc.), and can be easily separated by the advantages of these dissimilarity. Diastereomers can be separated by chromatography, preferably by separation / resolving techniques based on differences in solubility. Then, by any practical means that will not racemize, the optically pure enantiomer is recovered, together with the resolving agent. A more detailed description of techniques suitable for resolving stereoisomers of compounds starting from racemic mixtures can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981.

[0313] The reaction can be monitored by any suitable method known in the art. For example, the reaction can be monitored by spectroscopic means such as nuclear magnetic resonance (NMR) spectroscopy (e.g. 1 H or 13 C), infrared (IR) spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry (MS), or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).

[0314] Overview of general reaction schemes and synthetic routes

[0315] Compound I can be obtained by the synthetic route in Scheme 1. Specifically, compound B forms compound A under the condition of a deprotecting agent (e.g., an alcohol solution of an inorganic acid), and then compound A reacts with a methylating agent (e.g., trideuterated iodomethane, deuterated formaldehyde heavy aqueous solution and NaBD3CN, deuterated paraformaldehyde, deuterated formic acid, deuterated methanol and bis(triphenylphosphine)cyclopentadienylruthenium (II) chloride, iodomethane, formaldehyde aqueous solution and NaBH3CN, paraformaldehyde and formic acid, methanol and bis(triphenylphosphine)cyclopentadienylruthenium (II) chloride) to obtain compound A. Compound A is subjected to chiral resolution to obtain compounds IA and IB.

[0316] Solution 1

[0317]

[0318] wherein PG1 is selected from the group consisting of Boc, Cbz, Fmoc, Alloc, Teco, formyl, acetyl, trifluoroacetyl, phthalimide, trityl, Bn, p-methoxybenzyl and Ts.

[0319] The key intermediate compound B can be prepared by method A / A' of the synthetic route in Scheme 2. Compound B can be cyclized from the open-chain compound Ca through amide formation. The cyclization reaction can use a strong base (e.g., 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene) to directly form an amide bond (method A), or first hydrolyze the ester functional group in compound Ca and then form an amide bond through a coupling reagent (e.g., TBTU, HATU) (method A').

[0320] Alternatively, compound B can be prepared by method B of the synthetic route in Scheme 2. Compound B can be cyclized from open-chain compound Cb through ether formation. The cyclization reaction can directly form an ether bond through a Mitsonobu reaction, or the alcohol group in compound Cb can be first converted into a halogen or sulfonic acid and then the ether bond can be formed through a nucleophilic substitution reaction.

[0321] Solution 2

[0322]

[0323] Where R is selected from C 1-6 Alkyl, phenyl, etc.

[0324] The key intermediate Ca can be prepared by the synthetic route in Scheme 3. Compound Ca can be prepared from the reduction of compound E and the cyclization reaction of compound D mediated by cyanogen bromide.

[0325] Solution 3

[0326]

[0327] Pharmaceutical compositions, preparations and kits

[0328] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention (also referred to as an "active ingredient") and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises an effective amount of the active ingredient. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of the active ingredient. In some embodiments, the pharmaceutical composition comprises a preventively effective amount of the active ingredient.

[0329] The pharmaceutically acceptable excipient used in the present invention refers to a non-toxic carrier, adjuvant or medium that does not destroy the pharmacological activity of the compound formulated together. The pharmaceutically acceptable carrier, adjuvant or medium that can be used in the composition of the present invention include, but are not limited to, ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate), disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, silica gel, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based materials, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and lanolin.

[0330] The present invention also includes a kit (e.g., a pharmaceutical package). The kit provided may include a compound of the invention, other therapeutic agents, and a first and second container (e.g., a vial, an ampoule, a bottle, a syringe, and / or a dispersible package or other suitable container) containing the compound of the invention and other therapeutic agents. In some embodiments, the kit provided may also optionally include a third container containing a pharmaceutical excipient for diluting or suspending the compound of the invention and / or other therapeutic agents. In some embodiments, the compound of the invention and other therapeutic agents provided in the first container and the second container are combined to form a unit dosage form.

[0331] Pharmaceutical composition provided by the invention can be administered by many ways, including but not limited to: oral administration, parenteral administration, inhalation administration, topical administration, rectal administration, nasal administration, oral administration, vaginal administration, administration by implant or other modes of administration. For example, parenteral administration used herein includes subcutaneous administration, intradermal administration, intravenous administration, intramuscular administration, intraarticular administration, intraarterial administration, intrasynovial cavity administration, intrasternal administration, intrathecal administration, intralesional administration and intracranial injection or infusion technology.

[0332] Generally, an effective amount of the compounds provided herein is administered. The amount of the compound actually administered can be determined by a physician according to the relevant circumstances, including the condition being treated, the route of administration selected, the compound actually administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, and the like.

[0333] When used to prevent the conditions described herein, the compounds provided herein are administered to a subject at risk of developing the condition, typically based on the advice of a physician and under the supervision of a physician, at dosage levels as described above. Subjects at risk of developing a specific condition typically include those with a family history of the condition, or those identified by genetic testing or screening as being particularly susceptible to developing the condition.

[0334] The pharmaceutical compositions provided herein can also be administered over a long period of time ("chronic administration"). Chronic administration refers to administration of a compound or a pharmaceutical composition thereof over a long period of time, e.g., 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, etc., or administration may continue indefinitely, e.g., for the rest of the subject's life. In some embodiments, chronic administration is intended to provide a constant level of the compound in the blood over a long period of time, e.g., within a therapeutic window.

[0335] Various methods of administration can be used to further deliver the pharmaceutical composition of the present invention. For example, in some embodiments, the pharmaceutical composition can be administered by push injection, for example, in order to quickly increase the concentration of the compound in the blood to an effective level. The push dose depends on the target systemic level of the active component, for example, the intramuscular or subcutaneous push dose slowly releases the active component, and the push delivered directly to the vein (for example, by IV intravenous drip) can be delivered more quickly, so that the concentration of the active component in the blood is quickly increased to an effective level. In other embodiments, the pharmaceutical composition can be given in a continuous infusion form, for example, by IV intravenous drip, so as to provide a steady-state concentration of the active component in the subject's body. In addition, in other embodiments, the pharmaceutical composition of the push dose can be first given, and then continuous infusion.

[0336] Oral compositions can be in the form of bulk liquid solutions or suspensions or bulk powders. However, more generally, in order to facilitate accurate dosing, the composition is provided in unit dosage form. The term "unit dosage form" refers to a physical discrete unit suitable as a unit dose for human patients and other mammals, each unit containing a predetermined amount of active substances suitable for producing the desired therapeutic effect and a suitable pharmaceutical excipient. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes of liquid compositions, or pills, tablets, capsules, etc. in the case of solid compositions. In such compositions, the compound is usually a relatively small component (about 0.1 to about 50% by weight, or preferably about 1 to about 40% by weight), and the remainder is various carriers or excipients and processing aids useful for forming the desired administration form.

[0337] For oral dosage, a representative regimen is one to five oral doses per day, especially two to four oral doses, typically three oral doses. Using these dosage modes, each dose provides about 0.01 to about 20 mg / kg of the compound of the invention, and preferred doses each provide about 0.1 to about 10 mg / kg, especially about 1 to about 5 mg / kg.

[0338] In order to provide blood levels similar to those using an injectable dose, or lower blood levels than using an injectable dose, a transdermal dose is generally selected in an amount of about 0.01 to about 20% by weight, preferably about 0.1 to about 20% by weight, preferably about 0.1 to about 10% by weight, and more preferably about 0.5 to about 15% by weight.

[0339] From about 1 to about 120 hours, especially 24 to 96 hours, the injected dosage level is in the range of about 0.1 mg / kg / hour to at least 10 mg / kg / hour. In order to obtain sufficient steady state levels, a preload bolus of about 0.1 mg / kg to about 10 mg / kg or more may also be given. For a 40 to 80 kg human patient, the maximum total dose cannot exceed about 2 g / day.

[0340] Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous carrier and buffers, suspending and dispersing agents, colorants, flavoring agents, etc. Solid forms may include, for example, any of the following components, or compounds of a similar nature: binders, such as microcrystalline cellulose, tragacanth, or gelatin; excipients, such as starch or lactose, disintegrants, such as alginic acid, Primogel, or corn starch; lubricants, such as magnesium stearate; glidants, such as colloidal silicon dioxide; sweeteners, such as sucrose or saccharin; or flavoring agents, such as peppermint, methyl salicylate, or orange flavoring.

[0341] Injectable compositions are typically based on injectable sterile saline or phosphate buffered saline, or other injectable excipients known in the art. As previously mentioned, in such compositions, the active compound is typically a minor component, often about 0.05 to 10% by weight, and the remainder is an injectable excipient, etc.

[0342] Typically, transdermal compositions are formulated as topical ointments or creams containing active ingredients. When formulated as an ointment, the active ingredient is typically combined with a paraffin or water-miscible ointment base. Alternatively, the active ingredient can be formulated as an ointment together with, for example, an oil-in-water cream base. Such transdermal formulations are well known in the art and typically include other components for enhancing the stable skin penetration of the active ingredient or formulation. All such known transdermal formulations and components are included within the scope provided by the invention.

[0343] The compounds of the invention may also be administered by transdermal means. Thus, transdermal administration may be achieved using patches of the reservoir or porous membrane type, or a variety of solid matrices.

[0344] The above components for oral administration, injection or topical administration are representative only. Other materials and processing techniques are described in Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, Part 8, which is incorporated herein by reference.

[0345] The compounds of the invention may also be administered in sustained release form or from a sustained release delivery system. Descriptions of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.

[0346] The present invention also relates to pharmaceutically acceptable formulations of the compounds of the present invention. In one embodiment, the formulation comprises water. In another embodiment, the formulation comprises a cyclodextrin derivative. The most common cyclodextrins are α-, β- and γ-cyclodextrins consisting of 6, 7 and 8 α-1,4-linked glucose units, respectively, which optionally include one or more substituents on the linked sugar moiety, including but not limited to: methylated, hydroxyalkylated, acylated and sulfoalkyl ether substitutions. In some embodiments, the cyclodextrin is a sulfoalkyl ether β-cyclodextrin, for example, sulfobutyl ether β-cyclodextrin, also known as Captisol. See, for example, US5,376,645. In some embodiments, the formulation includes hexapropyl-β-cyclodextrin (e.g., in water, 10-50%).

[0347] Indications

[0348] In one aspect, the disease to be treated and / or prevented with the compounds of formula (I) (including all individual embodiments and generic subsets disclosed herein) or in the medical use, treatment and / or prevention methods as defined herein is selected from lung cancer, brain cancer, colorectal cancer, bladder cancer, urothelial cancer, breast cancer, ovarian cancer, head and neck cancer, pancreatic cancer, gastric cancer and mesothelioma, including metastases (especially brain metastases) of all cancers listed.

[0349] In another aspect, the disease treated and / or prevented with a compound of formula (I) or in a medical use, treatment and / or prevention method as defined herein is lung cancer. Preferably, the lung cancer is non-small cell lung cancer (NSCLC), including, for example, locally advanced or metastatic NSCLC, NSCLC adenocarcinoma, NSCLC with squamous histology, and NSCLC with non-squamous histology. More preferably, the lung cancer is NSCLC adenocarcinoma.

[0350] In another aspect, the disease to be treated and / or prevented with the compounds of formula (I) or in the medical use, treatment and / or prevention methods as defined herein is a disease carrying the EGFR genotype, preferably, the disease is cancer carrying the EGFR genotype. Specifically, the EGFR genotype is selected from EGFR del19, EGFR del19 T790M, EGFR del19 C797S, EGFR del19 C797X (preferably C797G or C797N), EGFR del19 T790M C797S, EGFR del19 T790MC797X (preferably C797G or C797N), EGFR del19 L792X (preferably L792F, L792H or L792Y), EGFR del19T790M L792X (preferably L792F, L792H or L792Y), EGFR L858R, EGFR L858R T790M, EGFR L858RC797S, EGFR L858R C797X (preferably C797G or C797N), EGFR L858R T790M C797S, EGFR L858RT790M C797X (preferably C797G or C797N), EGFR L858R L792X (preferably L792F, L792H or L792Y), EGFR L858R T790M L792X (preferably L792F, L792H or L792Y).

[0351] Therefore, in one aspect, the cancer is a cancer carrying the EGFRdel19 genotype. Preferably, cancer patients carrying the EGFRdel19 genotype are administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as first-line treatment, i.e., the patient is first receiving treatment with an EGFR inhibitor.

[0352] In another aspect, the cancer is a cancer carrying the EGFRdel19 T790M genotype. Preferably, cancer patients carrying the EGFRdel19 T790M genotype are administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a second-line treatment, i.e., patients who have progressed after first-line treatment with a first-generation or second-generation EGFR inhibitor (i.e., treatment with gefitinib, erlotinib, afatinib or dacomitinib).

[0353] In another aspect, the cancer is a cancer carrying the EGFRdel19 C797S genotype. Preferably, cancer patients carrying the EGFRdel19 C797S genotype are administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a second-line treatment, i.e., patients who have progressed after first-line treatment with a third-generation EGFR inhibitor (i.e., treatment with osimertinib, ametinib, or vometinib).

[0354] On the other hand, the cancer is a cancer carrying the EGFR del19 C797X (preferably C797G or C797N) genotype. Preferably, cancer patients carrying the EGFR del19 C797X (preferably C797G or C797N) genotype are administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a second-line treatment, i.e., patients who have progressed after first-line treatment with a third-generation EGFR inhibitor (i.e., treatment with osimertinib, ametinib, vometinib).

[0355] In another aspect, the cancer is a cancer carrying the EGFR del19 T790M C797S genotype. Preferably, a cancer patient carrying the EGFR del19 T790M C797S genotype is administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a third-line treatment, i.e., the patient has progressed on a first-line therapy with a first or second-generation EGFR inhibitor after acquiring T790M (i.e., treatment with gefitinib, erlotinib, afatinib or dacomitinib), and the patient has progressed on a second-line therapy with a third-generation EGFR inhibitor after acquiring C797S (i.e., with osimertinib, ametinib or vometinib).

[0356] On the other hand, the cancer is a cancer carrying the EGFR del19 T790M C797X (preferably C797G or C797N) genotype. Preferably, a cancer patient carrying the EGFR del19 T790M C797X (preferably C797G or C797N) genotype is administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a third-line treatment, i.e., the patient has progressed on a first-line therapy with a first or second-generation EGFR inhibitor (i.e., gefitinib, erlotinib, afatinib or dacomitinib) after acquiring T790M, and the patient has progressed after a second-line therapy with a third-generation EGFR inhibitor (i.e., osimertinib, ametinib or vometinib) after acquiring C797X (preferably C797G or C797N).

[0357] On the other hand, the cancer is a cancer carrying the EGFR del19 L792X (preferably L792F, L792H or L792Y) genotype. Preferably, cancer patients carrying the EGFR del19 L792X (preferably L792F, L792H or L792Y) genotype are administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a second-line treatment, i.e., patients who have progressed after first-line treatment with a third-generation EGFR inhibitor (i.e., treatment with osimertinib, ametinib, vometinib).

[0358] On the other hand, the cancer is a cancer carrying the EGFR del19 T790M L792X (preferably L792F, L792H or L792Y) genotype. Preferably, a cancer patient carrying the EGFR del19 T790M L792X (preferably L792F, L792H or L792Y) genotype is administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a third-line treatment, i.e., the patient progresses after acquiring T790M to a first-line therapy using a first or second-generation EGFR inhibitor (i.e., gefitinib, erlotinib, afatinib or dacomitinib treatment), and the patient progresses after acquiring L792X (preferably L792F, L792H or L792Y) after a second-line therapy using a third-generation EGFR inhibitor (i.e., osimertinib, ametinib or vometinib).

[0359] In one aspect, the cancer is a cancer carrying the EGFR L858R genotype. Preferably, a cancer patient carrying the EGFR L858R genotype is administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a first-line treatment, i.e., the patient is receiving treatment with an EGFR inhibitor for the first time.

[0360] In another aspect, the cancer is a cancer carrying the EGFR L858R T790M genotype. Preferably, cancer patients carrying the EGFR L858R T790M genotype are administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a second-line treatment, i.e., patients who have progressed after first-line treatment with a first-generation or second-generation EGFR inhibitor (i.e., treatment with gefitinib, erlotinib, afatinib or dacomitinib).

[0361] In another aspect, the cancer is a cancer carrying the EGFR L858R C797S genotype. Preferably, cancer patients carrying the EGFR L858R C797S genotype are administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a second-line treatment, i.e., patients who have progressed after first-line treatment with a third-generation EGFR inhibitor (i.e., treatment with osimertinib, ametinib, vometinib).

[0362] In another aspect, the cancer is a cancer carrying the EGFR L858R C797X (preferably C797G or C797N) genotype. Preferably, cancer patients carrying the EGFR L858R C797X (preferably C797G or C797N) genotype are administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a second line of treatment, i.e., patients who have progressed after first line treatment with a third generation EGFR inhibitor (i.e., treatment with osimertinib, ametinib, vometinib).

[0363] In another aspect, the cancer is a cancer carrying the EGFR L858R T790M C797S genotype. Preferably, a cancer patient carrying the EGFR L858R T790M C797S genotype is administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a third line of treatment, i.e., the patient has progressed on a first line of therapy with a first or second generation EGFR inhibitor after acquiring T790M (i.e., treatment with gefitinib, erlotinib, afatinib or dacomitinib), and the patient has progressed on a second line of therapy with a third generation EGFR inhibitor after acquiring C797S (i.e., with osimertinib, ametinib or vometinib).

[0364] In another aspect, the cancer is a cancer carrying the EGFR L858R T790M C797X (preferably C797G or C797N) genotype. Preferably, a cancer patient carrying the EGFR L858R T790M C797X (preferably C797G or C797N) genotype is administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a third line of treatment, i.e., the patient has progressed on a first line of therapy with a first or second generation EGFR inhibitor (i.e., treatment with gefitinib, erlotinib, afatinib or dacomitinib) after acquiring T790M, and the patient has progressed after a second line of therapy with a third generation EGFR inhibitor (i.e., with osimertinib, ametinib or vometinib) after acquiring C797X (preferably C797G or C797N).

[0365] On the other hand, the cancer is a cancer carrying the EGFR L858R L792X (preferably L792F, L792H or L792Y) genotype. Preferably, cancer patients carrying the EGFR L858R L792X (preferably L792F, L792H or L792Y) genotype are administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a second line of treatment, i.e., patients who have progressed after first line treatment with a third generation EGFR inhibitor (i.e., treatment with osimertinib, ametinib, vometinib).

[0366] On the other hand, the cancer is a cancer carrying the EGFR L858R T790M L792X (preferably L792F, L792H or L792Y) genotype. Preferably, a cancer patient carrying the EGFR L858R T790M L792X (preferably L792F, L792H or L792Y) genotype is administered a compound of formula (I) (including all individual embodiments and generic subsets disclosed herein) as a third line of treatment, i.e., the patient has progressed on a first line of therapy with a first or second generation EGFR inhibitor (i.e., treatment with gefitinib, erlotinib, afatinib or dacomitinib) after acquiring T790M, and the patient has progressed on a second line of therapy with a third generation EGFR inhibitor (i.e., with osimertinib, ametinib or vometinib) after acquiring L792X (preferably L792F, L792H or L792Y).

[0367] Combination therapy

[0368] In another aspect, the pharmacologically active substance used together / in combination with the compounds of formula (I) (including all individual embodiments and generic subsets disclosed herein) or in the medical use, use, treatment and / or prevention methods as defined herein may be selected from any one or more of the following (preferably, only one additional pharmacologically active substance is used in all these embodiments):

[0369] 1. Inhibitors of EGFR and / or inhibitors of its variants

[0370] a. EGFR inhibitors, for example, gefitinib, icotinib, afatinib, dacomitinib, lapatinib, osimertinib, ametinib, and vometinib;

[0371] b. EGFR antibodies, for example, cetuximab, panitumumab, necituzumab.

[0372] 2. MEK inhibitors and / or inhibitors of their variants

[0373] For example, trametinib, cobimetinib, binimetinib, selumetinib, and refametinib.

[0374] 3. c-MEK inhibitors and / or inhibitors of its variants

[0375] a. For example, savolitinib, cabozantinib, and foretinib;

[0376] b. MEK antibodies, for example, emibetuzumab.

[0377] 4. Mitosis inhibitors

[0378] For example, CDK4 / 6 inhibitors, such as palbociclib, ribociclib, abemaciclib.

[0379] 5. Immunotherapeutic agents

[0380] a. immune checkpoint inhibitors, for example, anti-CTLA4 mAB, anti-PD1 mAb, anti-PD-L2 mAb, anti-LAG3 mAb or anti-TIM3 mAb; preferably, anti-PD1 mAb; preferably, for example, ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, pidilzumab, PDR-001 (BAP049-clone-E, disclosed and used in WO2017 / 019896);

[0381] b. Immunomodulators

[0382] For example, a CD73 inhibitor or a CD73 inhibitor antibody.

[0383] 6. Anti-angiogenic agents

[0384] For example, bevacizumab, nintedanib;

[0385] 7. Apoptosis Inducers

[0386] a. Bcl-2 inhibitors

[0387] For example, venetoclax, obatoclax, and Navitoclax;

[0388] b. Mcl-1 inhibitors

[0389] For example, AZD-5991, AMG-176, S-64315.

[0390] 8. mTOR inhibitors

[0391] For example, rapaloxin, temsirolimus, everolimus, and rifolimus.

[0392] 9. Histone deacetylase inhibitors

[0393] 10. IL6 inhibitors

[0394] 11.JAK inhibitors

[0395] Example

[0396] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only intended to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, parts and percentages are by weight and weight percentage.

[0397] Preparation of intermediate F-1 2-(5-hydroxy-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinic acid methyl ester hydrochloride

[0398]

[0399] The following synthetic route was used

[0400]

[0401] Step 1 Synthesis of compound 2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one

[0402] 1-methyl-1H-pyrazole-5-alcohol (49.0g, 0.5mol) and acetonitrile (1.5L) were added to a 3L single-necked flask equipped with magnetic stirring successively, stirred and dissolved, potassium carbonate (138.0g, 1.0mmol) was added, stirred at room temperature for half an hour, SEM-Cl (124.5g, 0.75mol) was slowly added dropwise, and the reaction was stirred at room temperature overnight under nitrogen. Insoluble solids were filtered out, washed with acetonitrile (100mL), the filtrate was concentrated to dryness, water (200mL) was added, MTBE was extracted (300mLx3), dried over anhydrous sodium sulfate, filtered, and concentrated to the time when solid was precipitated, stopped concentrating, petroleum ether (1.5L) was added under stirring, a large amount of white solid was precipitated, filtered, washed with petroleum ether (100mL), and the filter cake was dried in vacuo to obtain 70.5g of the white solid, with a yield of 61.84%. LC-MS (APCI): m / z = 229.2 (M+1) + . 1 H NMR (500MHz, CDCl3) δ (ppm): 7.29 (d, J = 3.5Hz, 1H), 5.49 (d, J = 3.5Hz, 1H), 4.99 (s, 2H), 3.47-3.43 (m, 5H), 0.89-0.86 (m, 2H), 0.00 (s, 9H).

[0403] Step 2 Synthesis of Compound 4-iodo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one

[0404] 2-Methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (45.6 g, 0.2 mol) and acetonitrile (1.0 L) were added to a 3L single-mouth bottle equipped with a magnetic stirrer, stirred to dissolve, cooled in an ice-water bath, and NIS (44.8 g, 0.2 mol) was slowly added. After the addition, the ice-water bath was removed, and the reaction was stirred at room temperature under nitrogen for 2 hours. The mixture was concentrated under reduced pressure, and ethyl acetate (300 mL) and saturated sodium bicarbonate aqueous solution (200 mL) were added to the residue, stirred for 10 minutes, and the organic phase was separated. The aqueous phase was extracted with ethyl acetate (200 mL), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated until solids precipitated. The concentration was stopped, and petroleum ether (600 mL) was added under stirring to precipitate a large amount of yellow solids, which were filtered, washed with petroleum ether (50 mL), and the filter cake was dried under vacuum to obtain 60.5 g of the yellow solid, with a yield of 85.5%. LC-MS (APCI): m / z = 355.1 (M+1) + . 1H NMR (500MHz, CDCl3) δ (ppm): 7.43 (s, 1H), 4.98 (s, 1H), 3.49-3.43 (m, 5H), 0.89-0.84 (m, 2H), 0.89-0.86 (m, 2H), 0.00 (s, 9H).

[0405] Step 3: Synthesis of Compound 2-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isonicotinic acid methyl ester

[0406] To a 3 L three-necked flask equipped with a magnetic stirrer was added methyl 2-chloroisonicotinoate (80 g, 0.47 mol), the flask was evacuated and replaced with nitrogen three times, and the flask was set aside under nitrogen.

[0407] To another 3L three-necked flask equipped with magnetic stirring, add bis(pyrazol)boronic acid (142g, 0.56mol), methoxy(cyclooctadiene) iridium dimer (5.5g, 8.3mmol) and DBBPY (4.5g, 16.8mmol) in sequence, evacuate and replace with nitrogen three times, draw in anhydrous MTBE (1.2L), stir under nitrogen for 15 minutes, and obtain a brown-red solution. The solution was drawn into the reaction bottle of methyl 2-chloroisonicotinyl under nitrogen, and stirred at room temperature for 64 hours under nitrogen. The insoluble solid was filtered out, and the filtrate was concentrated to dryness under reduced pressure. Petroleum ether (200mL) was added to the residue and stirred for 20 minutes. A large amount of off-white solid was precipitated, filtered, washed with petroleum ether (20mL), and vacuum dried to obtain 61.5g of off-white solid, with a yield of 44.0%. LC-MS (APCI): m / z=298.1 (M+1) + . 1 HNMR(400MHz, CDCl3)8.24(s,1H),7.88(s,1H),3.95(s,3H),1.37(s,12H).

[0408] Step 4: Synthesis of Compound 2-chloro-6-(2-methyl-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)isonicotinic acid methyl ester

[0409] To a 1L single-necked bottle equipped with a magnetic stirrer and a condenser, 4-iodo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (35.4 g, 0.1 mol), 2-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isonicotinic acid methyl ester (35.6 g, 0.12 mol), Pd2(dba)3 (2.28 g, 2.5 mmol), n-butyldi(1-adamantyl)phosphine (2.87 g, 8 mmol), cesium carbonate (97.7 g, 0.3 mol), toluene (250 mL) and water (80 mL) were added in sequence, the mixture was evacuated and replaced with nitrogen three times, the temperature was raised to 50°C and the reaction was stirred and kept warm for 2 hours. Cool to room temperature, filter out insoluble solids, separate the organic phase, extract the aqueous phase with ethyl acetate (100 mL x 2), combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate and pass through a silica gel column to obtain 28.5 g of off-white solid, with a yield of 71.8%. LC-MS (APCI): m / z = 398.1 (M+1) + . 1 HNMR (500MHz, CDCl3) δ (ppm): 8.84 (d, J = 1.5 Hz, 1H), 8.15 (s, 1H), 7.64 (d, J = 1.5 Hz, 1H), 5.16 (s,2H),3.94(s,3H),3.55(s,3H),3.51(t,J=8.0Hz,2H),0.90(t,J=8.0Hz,2H),0.01(s,9H).

[0410] Step 5: Synthesis of Compound 2-methyl-6-(2-methyl-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)isonicotinic acid methyl ester

[0411] To a 1L single-necked bottle equipped with a magnetic stirrer and a condenser, methyl 2-chloro-6-(2-methyl-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)isonicotinoate (27.8 g, 70 mmol), Pd2(dba)3 (1.95 g, 2.13 mmol), n-butyldi(1-adamantyl)phosphine (2.28 g, 6.36 mmol), cesium carbonate (68.3 g, 210 mmol) and 1,4-dioxane (350 mL) were added in sequence. The mixture was evacuated and replaced with nitrogen three times. Trimethylcyclotriboroxane (40 mL, 140 mmol, 3.5 M tetrahydrofuran solution) was added dropwise under a nitrogen atmosphere. After the dropwise addition, the temperature was raised to 80°C and the mixture was stirred and reacted overnight. Cool to room temperature, filter out insoluble solids, wash with ethyl acetate (20 mL), concentrate the filtrate to dryness, add water (150 mL) and ethyl acetate (150 mL), stir for 10 minutes, separate the organic phase, extract the aqueous phase with ethyl acetate (100 mL x 2), combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate and pass through a silica gel column to obtain 20.5 g of a yellow solid, with a yield of 77.7%. LC-MS (APCI): m / z = 378.1 (M+1) + .

[0412] Step 5 Synthesis of intermediate compound F-1

[0413] Add 2-methyl-6-(2-methyl-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)isonicotinic acid methyl ester (20g, 53.1mmol) and ethyl acetate (100mL) in sequence to a 250mL single-mouth bottle equipped with magnetic stirring, stir to dissolve, add 5M HCl isopropanol solution (60mL) dropwise, and stir under nitrogen for 3 hours. A large amount of yellow solid precipitates, add ethyl acetate (100mL) to dilute, filter, wash with ethyl acetate (30mL), and vacuum dry to obtain 14.5g of the yellow solid, with a yield of 96.6%. LC-MS (APCI): m / z=248.1 (M+1) + .

[0414] Intermediate F-2 2-(5-hydroxy-1-(methyl-d3)-1H-pyrazol-4-yl)-6-methylisonicotinic acid methyl ester hydrochloride Salt preparation

[0415]

[0416] The following synthetic route was used

[0417]

[0418] Step 1: Synthesis of Compound 2-Benzalhydrazine-1-carboxylic Acid Tert-Butyl Ester

[0419] Add tert-butyloxycarbonylhydrazine (26.4 g, 0.2 mol) and anhydrous THF (200 mL) to a 500 mL single-necked flask equipped with a magnetic stirrer, stir to dissolve, add benzaldehyde (27.6 g, 0.26 mol), stir and react at room temperature under nitrogen overnight. A large amount of white solid precipitates, add petroleum ether (200 mL), stir for 10 minutes, filter, wash with petroleum ether (20 mL), and vacuum dry to obtain 37.6 g of the white solid, with a yield of 85.5%.

[0420] Step 2: Synthesis of Compound 2-benzylidene-1-(methyl-d3)hydrazine-1-carboxylic acid tert-butyl ester

[0421] Sodium hydride (7.1 g, 177.3 mmol, w / w 60%) was added to a 500 mL three-necked flask equipped with magnetic stirring, vacuumized and replaced with nitrogen three times, cooled in an ice-water bath, anhydrous THF (250 mL) was injected, and an anhydrous THF solution of 2-benzylidenehydrazine-1-formic acid tert-butyl ester (30 g, 136.4 mmol, 50 mL) was added dropwise under stirring, stirred for 10 minutes, iodomethane-d3 (23.7 g, 163.7 mmol) was added dropwise, the ice bath was removed, and the reaction was stirred at room temperature under nitrogen for 3 hours. Saturated aqueous ammonium chloride solution (100 mL) was added to quench the reaction, the organic phase was separated, the aqueous phase was extracted with ethyl acetate (100 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain 26.3 g of a light yellow solid with a yield of 81.3%. 1 H NMR (400MHz, CDCl3) δ (ppm): 7.68-7.74 (m, 2H), 7.65 (s, 1H), 7.29-7.44 (m, 3H), 1.59 (s, 9H).

[0422] Step 3 Synthesis of Compound 1-(methyl-d3)hydrazine-1-carboxylic acid tert-butyl ester

[0423] At the same time, tert-butyl 2-benzylidene-1-(methyl-d3)hydrazine-1-carboxylate (5.0 g, 21 mol) and methanol (100 mL) were added to five 250 mL single-necked flasks equipped with magnetic stirring, stirred to dissolve, added Pd / C (0.6 g, w / w 10%), evacuated and replaced with hydrogen 3 times, heated to 50 ° C under a hydrogen balloon atmosphere and stirred overnight. Cooled to room temperature, combined treatment, filtered to remove the catalyst, washed the filter cake with methanol (30 mL), and concentrated the filtrate to dryness to obtain 15.7 g of brown oil with a yield of 100%, which was directly used in the next step.

[0424] Step 4: Synthesis of Compound (Methyl-d3) Hydrazine Dihydrochloride

[0425] 5M hydrochloric acid isopropanol solution (150 mL) was added to a 250 mL single-necked flask containing tert-butyl 1-(methyl-d3)hydrazine-1-carboxylate (15.7 g, 105 mmol), and the mixture was stirred at room temperature under nitrogen overnight. The solvent was evaporated under reduced pressure to obtain 12.8 g of a brown solid with a yield of 100%, which was directly used in the next step.

[0426] Step 5 Synthesis of Compound 1-(methyl-d3)-1H-pyrazole-5-ol

[0427] To a 250mL single-necked flask containing (methyl-d3)hydrazine dihydrochloride (12.8g, 105mmol), water (75mL) was added, and the pH was adjusted to 9.5 with 50% NaOH aqueous solution using precision pH test paper. The mixture was heated to 40°C, and 3-methoxyacrylate (11g, 94.5mmol) was slowly added. The addition was completed in 1 hour. After the addition was completed, the pH was adjusted to 9.0-9.5 with 50% NaOH aqueous solution. TLC monitoring was performed. When the 3-methoxyacrylate point disappeared, the reaction was continued with stirring for 3 hours at room temperature. During this period, the pH was controlled to 9.0-9.5. The mixture was cooled to room temperature and then cooled in an ice-water bath. The pH was adjusted to 3-4 with 6M hydrochloric acid aqueous solution. The mixture was extracted with dichloromethane (60mLx5). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain 5.2g of a white solid with a yield of 49.0%, which was directly used in the next step.

[0428] Step 6 Synthesis of Compound 2-(methyl-d3)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one

[0429] Acetonitrile (100mL) was added to a 250mL single-necked flask containing 1-(methyl-d3)-1H-pyrazole-5-ol (5.2g, 51.4mmol), stirred and dissolved, potassium carbonate (10.6g, 77.1mmol) was added, stirred at room temperature for half an hour, SEM-Cl (11.2g, 66.8mol) was slowly added dropwise, and the reaction was stirred at room temperature under nitrogen overnight. Ethyl acetate (100mL) was added to dilute the reaction solution, insoluble solids were filtered out, washed with ethyl acetate (10mL), the filtrate was concentrated to dryness, water (200mL) was added, ethyl acetate was extracted (60mLx3), dried over anhydrous sodium sulfate, filtered, concentrated to solid precipitation, stopped concentrating, petroleum ether (50mL) was added under stirring, a large amount of white solid was precipitated, filtered, washed with petroleum ether (5mL), and the filter cake was dried in vacuo to obtain 6.56g of the white solid, with a yield of 55.2%. LC-MS (APCI): m / z = 232.2 (M+1) + .

[0430] Step 7 Synthesis of Compound 4-iodo-2-(methyl-d3)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one

[0431] Add 2-(methyl-d3)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (6.5 g, 28.1 mmol) and acetonitrile (100 L) to a 250 single-mouth bottle equipped with a magnetic stirrer, stir to dissolve, cool in an ice-water bath, slowly add NIS (6.32 g, 28.1 mol), remove the ice-water bath after addition, stir and react at room temperature under nitrogen for 2 hours. Concentrate under reduced pressure, add ethyl acetate (100 mL) and saturated sodium bicarbonate aqueous solution (100 mL) to the residue, stir for 10 minutes, separate the organic phase, extract the aqueous phase with ethyl acetate (50 mL), combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate until solid precipitates, stop concentrating, add petroleum ether (60 mL) under stirring, precipitate a large amount of yellow solid, filter, wash with petroleum ether (5 mL), and dry the filter cake under vacuum to obtain 8.43 g of the yellow solid, with a yield of 84.0%. LC-MS (APCI): m / z = 358.1 (M+1) + .

[0432] Step 8 Synthesis of Compound 2-chloro-6-(2-(methyl-d3)-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)isonicotinic acid methyl ester

[0433] To a 250 mL single-necked bottle equipped with a magnetic stirrer and a condenser, 4-iodo-2-(methyl-d3)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydro-3H-pyrazol-3-one (7.16 g, 20 mmol), 2-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isonicotinic acid methyl ester (7.12 g, 24 mmol), Pd2(dba)3 (0.46 g, 0.5 mmol), n-butyldi(1-adamantyl)phosphine (0.57 g, 1.6 mmol), cesium carbonate (19.5 g, 60 mmol), toluene (60 mL) and water (20 mL) were added in sequence, the mixture was evacuated and replaced with nitrogen three times, the temperature was raised to 50°C and the reaction was stirred and kept warm for 2 hours. Cool to room temperature, filter out insoluble solids, separate the organic phase, extract the aqueous phase with ethyl acetate (50 mL x 2), combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate and pass through a silica gel column to obtain 5.80 g of off-white solid, with a yield of 72.3%. LC-MS (APCI): m / z = 401.1 (M+1) + .

[0434] Step 9: Synthesis of Compound 2-methyl-6-(2-(methyl-d3)-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)isonicotinic acid methyl ester

[0435] To a 250L single-necked bottle equipped with a magnetic stirrer and a condenser, methyl 2-chloro-6-(2-(methyl-d3)-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)isonicotinoate (5.80 g, 14.46 mmol), Pd2(dba)3 (0.41 g, 0.44 mmol), n-butyldi(1-adamantyl)phosphine (0.48 g, 1.32 mmol), cesium carbonate (14.2 g, 43.7 mmol) and 1,4-dioxane (70 mL) were added in sequence. The mixture was evacuated and replaced with nitrogen three times. Trimethylcyclotriboroxane (0.83 mL, 29.2 mmol, 3.5 M tetrahydrofuran solution) was added dropwise under nitrogen. After the dropwise addition, the temperature was raised to 80°C and the mixture was stirred and reacted overnight. Cool to room temperature, filter out insoluble solids, wash with ethyl acetate (20 mL), concentrate the filtrate to dryness, add water (150 mL) and ethyl acetate (150 mL), stir for 10 minutes, separate the organic phase, extract the aqueous phase with ethyl acetate (100 mL x 2), combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate and pass through a silica gel column to obtain 4.0 g of a yellow solid, with a yield of 72.5%. LC-MS (APCI): m / z = 381.1 (M+1) + .

[0436] Step 10 Synthesis of intermediate compound F-2

[0437] 2-Methyl-6-(2-(methyl-d3)-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)isonicotinic acid methyl ester (4.0g, 10.5mmol) and ethyl acetate (10mL) were added to a 100mL single-mouth bottle equipped with a magnetic stirrer, stirred to dissolve, and 5M HCl isopropanol solution (20mL) was added dropwise. The reaction was stirred for 3 hours under a nitrogen atmosphere. A large amount of yellow solid was precipitated, and ethyl acetate (50mL) was added to dilute, filtered, washed with ethyl acetate (5mL), and dried in vacuo to obtain 2.69g of the yellow solid, with a yield of 89.2%. LC-MS (APCI): m / z=251.1 (M+1) + .

[0438] Intermediate F-3 2-(5-hydroxy-1-methyl-1H-pyrazol-4-yl)-6-(methyl-d3)isonicotinic acid methyl ester hydrochloride Salt preparation

[0439]

[0440] The following synthetic route was used

[0441]

[0442] Step 1 Synthesis of compound 2,4,6-tri(methyl-d3)-1,3,5,2,4,6-trioxatriborane

[0443] Add trimethyl borate (50 mL) and anhydrous THF (500 mL) to a 2L three-necked flask equipped with magnetic stirring, evacuate and replace with nitrogen 3 times, cool to -78 ° C, slowly add deuterated methyl magnesium iodide (250 mL, 1M ether solution) dropwise, and drip completely in 2 hours. After the dripping is completed, keep warm and stir to react for 2 hours, dropwise add 1M hydrochloric acid aqueous solution (125 mL) within 10 minutes, warm to room temperature, add saturated brine (200 mL), filter out insoluble solids, wash with ether (20 mL), separate the organic phase, extract the aqueous phase with ether (60 mL x 3), combine the organic phases, wash with saturated brine (100 mL), dry with anhydrous sodium sulfate, filter, concentrate to about 100 mL, add pyridine (50 mL), and stir at room temperature overnight under nitrogen. A large amount of light yellow solid precipitates, filter, wash with ether (20 mL), and obtain 6.1 g of solid, which is directly used in the next step.

[0444] Step 2 Synthesis of Compound 2-(methyl-d3)-6-(2-methyl-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)isonicotinic acid methyl ester

[0445] To a 250 mL single-necked bottle containing crude 2,4,6-tris(methyl-d3)-1,3,5,2,4,6-trioxatriborane (6.1 g) was added 1,4-dioxane (70 mL). The container was stirred, and 2-chloro-6-(2-methyl-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)isonicotinoic acid methyl ester (2.90 g, 7.23 mmol), Pd2(dba)3 (0.22 g, 0.22 mmol), n-butyldi(1-adamantyl)phosphine (0.24 g, 0.66 mmol), and cesium carbonate (7.1 g, 21.8 mmol) were added in sequence. The mixture was evacuated and replaced with nitrogen three times. The temperature was raised to 80°C under a nitrogen atmosphere and the reaction was stirred and kept warm overnight. Cool to room temperature, filter out insoluble solids, wash with ethyl acetate (20 mL), concentrate the filtrate to dryness, add water (60 mL) and ethyl acetate (60 mL), stir for 10 minutes, separate the organic phase, extract the aqueous phase with ethyl acetate (50 mL x 2), combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate and pass through a silica gel column to obtain 1.5 g of a yellow solid. LC-MS (APCI): m / z = 381.1 (M+1) + .

[0446] Step 3 Synthesis of intermediate compound F-3

[0447] To a 100mL single-mouth bottle equipped with a magnetic stirrer, methyl 2-(methyl-d3)-6-(2-methyl-3-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1H-pyrazol-4-yl)isonicotinate (1.5g, 3.94mmol) and ethyl acetate (5mL) were added in sequence, stirred to dissolve, 5M HCl isopropanol solution (20mL) was added dropwise, and the reaction was stirred for 3 hours under nitrogen. A large amount of yellow solid was precipitated, ethyl acetate (50mL) was added to dilute, filtered, washed with ethyl acetate (5mL), and vacuum dried to obtain 1.04g of the yellow solid, with a yield of 92.6%. LC-MS (APCI): m / z=251.1 (M+1) + .

[0448] Preparation of Intermediate G-1 5-amino-4-methylvaleric acid ethyl ester hydrochloride

[0449]

[0450] The following synthetic route was used

[0451]

[0452] Step 1 Synthesis of compound 5-methylpiperidin-2-one

[0453] 5-Methylpyridin-2(1H)-one (5.45 g, 50 mmol) and methanol (500 mL) were added to five 1L single-mouth bottles equipped with magnetic stirring, stirred to dissolve, and Pd / C (5.0 g, 10%, wet) was added to each, vacuumed and replaced with hydrogen 3 times, and stirred under the pressure of a hydrogen balloon to react overnight. Pd / C was filtered off, washed with methanol (50 mL), the filtrate was combined, and concentrated to dryness under reduced pressure to obtain 28.25 g of a light yellow oil, with a yield of 100%. LC-MS (APCI): m / z=114.1 (M+1) + , 1 H NMR (500MHz, CDCl3) δ (ppm): 6.29 (br s,1H),3.31-3.26(m,1H),2.93-2.88(m,1H),2.43-2.29(m,2H),1.95-1 .92(m,1H),1.88-1.83(m,1H),1.50-1.42(m,1H),1.00(d,J=6.5Hz,3H).

[0454] Step 2 Synthesis of Compound 5-amino-4-methylpentanoic acid hydrochloride

[0455] 5-Methylpiperidin-2-one (28.25 g, 0.25 mol) and 6M hydrochloric acid aqueous solution (2.5 L) were added to a 3L single-mouth bottle equipped with a magnetic stirrer, and the temperature was raised to 90°C. The mixture was stirred and reacted overnight under nitrogen. The mixture was cooled to room temperature, and the hydrochloric acid aqueous solution and toluene with water (100 mL x 3) were evaporated under reduced pressure. The mixture was concentrated to dryness to obtain 41.75 g of white powder with a yield of 100%, which was used directly in the next step.

[0456] Step 3 Synthesis of intermediate compound G-1

[0457] Add 5-amino-4-methylpentane hydrochloride (41.75 g, 0.25 mol) and anhydrous ethanol (300 mL) in sequence to a 1L single-mouth bottle equipped with a magnetic stirrer, stir to dissolve, cool in an ice-water bath, slowly drop thionyl chloride (59.5 g, 0.5 mol) under nitrogen, remove the ice bath, stir and react at room temperature overnight. Concentrate to dryness under reduced pressure, add toluene (50 mL), and concentrate to dryness to obtain 48.75 g of white solid, which is directly used in the next step.

[0458] Preparation of Intermediate G-2 5-amino-4-methylvaleric acid ethyl ester hydrochloride

[0459]

[0460] The following synthetic route was used

[0461]

[0462] Step 1 Synthesis of compound 4-(benzyloxy)butyraldehyde

[0463] Add 4-(Benzyloxy)butane-1-ol (90 g, 0.5 mol) and dichloromethane (900 mL) to a 2L single-mouth bottle equipped with a magnetic stirrer, stir to dissolve, slowly add Dess-Martin reagent (254.5 g, 0.6 mol) under ice-water cooling, remove the ice bath, stir and react at room temperature for 1 hour under nitrogen atmosphere. Add sodium sulfite aqueous solution (300 mL) to quench the reaction, separate the organic phase, extract the aqueous phase with dichloromethane (200 mL), combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate to dryness. The residue is passed through a silica gel column to obtain 70 g of a colorless oil with a yield of 78.7%. 1 H NMR (400MHz, CDCl3) δ (ppm): 9.79 (s, 1H), 7.38-7.27 (m, 5H), 4.50 (s, 2H), 3.52 (t, J = 6.0Hz, 2H), 2.58-2.54 (m, 2H), 1.99-1.93 (m, 2H).

[0464] Step 2 Synthesis of Compound 5-(Benzyloxy)pentane-1,1,1-d3-2-ol

[0465] Add 4-(Benzyloxy)butyraldehyde (70g, 0.39mol) and anhydrous THF (700mL) to a 2L three-necked flask equipped with a magnetic stirrer, stir to dissolve, evacuate and replace with nitrogen three times, cool to 0°C, slowly dropwise add CD3MgI (470mL, 0.47mol, 1M THF solution), and after the dropwise addition, stir and react for 2 hours. Add saturated NH4Cl aqueous solution (300mL) to quench the reaction, separate the organic phase, extract the aqueous phase with ethyl acetate (200mLx2), combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate to dryness. The residue is passed through a silica gel column to obtain 65g of a colorless oil with a yield of 84.5%. 1 H NMR (400MHz, CDCl3) δ (ppm): 7.39-7.29 (m, 5H), 4.53 (s, 2H), 3.84-3.80 (m, 1H), 3.84-3.79(m,1H),3.52(t,J=6.0Hz,2H),1.77-1.70(m,2H),1.65-1.49(m,2H).

[0466] Step 3 Synthesis of compound (4-bromopentane-5,5,5-d3) benzyl ether

[0467] 5-(Benzyloxy)pentane-1,1,1-d3-2-ol (65 g, 0.33 mol), carbon tetrabromide (142.3 g, 0.43 mol) and triphenylphosphine (129.8 g, 0.5 mmol) were added to a 2L single-mouth bottle equipped with a magnetic stirrer, and the mixture was evacuated and replaced with nitrogen three times. Anhydrous dichloromethane (700 mL) was added under stirring under ice-water bath cooling. After the addition was completed, the ice bath was removed and the mixture was stirred at room temperature under nitrogen atmosphere for 2 hours. The solvent was concentrated to dryness under reduced pressure, petroleum ether (500 mL) was added, stirred for 20 minutes, insoluble solids were filtered out, and petroleum ether was washed (100 mL). The filtrate was concentrated and passed through a silica gel column to obtain 45 g of a colorless oil with a yield of 52.4%. 1 H NMR (300MHz, CDCl3) δ (ppm): 7.37-7.27 (m, 5H), 4.52 (s, 2H), 4.20-4.13 (m, 1H), 3.54-3.50 (m, 2H), 1.95-1.80 (m, 4H).

[0468] Step 4 Synthesis of Compound 5-(Benzyloxy)-2-(Methyl-d3)Valeronitrile

[0469] Add (4-bromopentane-5,5,5-d3) benzyl ether (45g, 173mmol) and anhydrous acetonitrile (450mL) to a 1L single-mouth bottle equipped with a magnetic stirrer, stir to dissolve, add TMSCN (25.7g, 260mmol) and TBAF solid (67.9g, 260mmol), evacuate and replace with nitrogen 3 times, heat to 80°C, keep warm and stir to react overnight. Cool to room temperature, evaporate the solvent under reduced pressure, add saturated brine (200mL) and ethyl acetate (300mL), stir for 5 minutes, separate the organic phase, extract the aqueous phase with ethyl acetate (150mL), combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate and pass through a silica gel column to obtain 23g of colorless oil, with a yield of 64.4%. LC-MS (APCI): m / z=207.2 (M+1) + .

[0470] Step 5 Synthesis of intermediate compound G-2

[0471] Add 5-(benzyloxy)-2-(methyl-d3)pentanenitrile (5 g, 24.2 mmol) and ethanol (100 mL) to two 250 mL single-mouth bottles equipped with magnetic stirring, stir evenly, add PtO2 (1.5 g), evacuate and replace with hydrogen 3 times, add dioxane hydrochloride solution (12.1 mL, 48.4 mmol, 4 M) through a syringe, stir at room temperature under hydrogen atmosphere overnight. Combine and treat, filter out the catalyst, wash with ethanol (20 mL), concentrate the filtrate to dryness, and use it directly in the next step.

[0472] Example 1(E)-1 1 ,2 6 ,7-Trimethyl-5 6 -((4-(methyl-d3)piperazin-1-yl)methyl)-5-(4-(methyl-d3)piperazin-1-yl)methyl)- 2 ,5 3 -Dihydro- 1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecane Fen-3-one (compound T-1);

[0473] (R,E)-1 1 ,2 6 ,7-Trimethyl-5 6 -((4-(methyl-d3)piperazin-1-yl)methyl)-5-(4-(methyl-d3)piperazin-1-yl)methyl)- 2 ,5 3 -Dihydro-1 1 H,5 1 H- 11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-3-one (Compound T-1-R);

[0474] (S,E)-1 1 ,2 6 ,7-Trimethyl-5 6 -((4-(methyl-d3)piperazin-1-yl)methyl)-5-(4-(methyl-d3)piperazin-1-yl)methyl)- 2 ,5 3 -Dihydro-1 1 H,5 1 H- 11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-3-one Preparation of (Compound T-1-S)

[0475]

[0476] The following synthetic route was used

[0477]

[0478] Step 1 Synthesis of Compound 4-(3-fluoro-4-nitrobenzyl)piperazine-1-carboxylic acid tert-butyl ester

[0479] 3-Fluoro-4-nitrobenzaldehyde (33.8 g, 0.2 mol), tert-butyl piperazine-1-carboxylate (44.6 g, 0.24 mol) and dichloromethane (500 mL) were added to a 1L single-mouth bottle equipped with a magnetic stirrer, stirred to dissolve, 4A powdered molecular sieves (20 g) were added, sodium tri(acetoxy)borohydride (84.8 g, 0.4 mmol) was added under an ice-water bath, the ice bath was removed, and the reaction was stirred overnight under nitrogen. Water (300 mL) was added to quench the reaction, insoluble solids were filtered off, the filter cake was washed with dichloromethane (40 mL), the filtrate was separated, the aqueous phase was extracted with dichloromethane (200 mL), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated and passed through a silica gel column to obtain 42.5 g of a yellow solid, with a yield of 62.7%. LC-MS (APCI): m / z=340.1 (M+1) + , 1 H NMR(500MHz, CDCl3)δ(ppm):8.03-8.00(m,1H),7.35-7.32(m,1H),7.26-7.25( m,1H),3.56(s,2H),3.45(t,J=5.0Hz,4H),2.40(t,J=5.0Hz,4H),1.45(s,9H).

[0480] Step 2 Synthesis of Compound 4-(3-((5-ethoxy-2-methyl-5-oxopentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylic acid tert-butyl ester

[0481] To a 500mL single-mouth bottle equipped with a condenser and magnetic stirring, tert-butyl 4-(3-fluoro-4-nitrobenzyl)piperazine-1-carboxylate (25g, 73.66mmol), intermediate G-1 (17.3g, 88.40mmol) and DMF (200mL) were added in sequence, potassium carbonate (25.4g, 184.15mmol) was slowly added under stirring, the temperature was raised to 60°C, and the reaction was stirred and kept warm overnight under nitrogen. After cooling to room temperature, the reaction solution was poured into dichloromethane (300mL), the inorganic salt was filtered off, and the solution was washed with dichloromethane (50mL). The filtrate was concentrated to dryness under reduced pressure and passed through a silica gel column to obtain 28.5g of a yellow oil with a yield of 80.8%. LC-MS (APCI): m / z=479.3 (M+1) + , 1H NMR (300MHz, CDCl3) δ (ppm): 8.20 (t, J = 4.8Hz, 1H), 7.12 (d, J = 9.0Hz, 1H), 6. 81(s,1H),6.63(dd,J=9.0Hz,J=1.5Hz,1H),4.14-4.12(m,2H),3.47-3.43(m, 6H),3.30-3.22(m,1H),3.16-3.08(m,1H),2.44-2.35(m,6H),1.93-1.85(m,2 H),1.60-1.56(m,1H),1.46(s,9H),1.28-1.25(m,3H),1.06(d,J=6.6Hz,3H).

[0482] Step 3 Synthesis of Compound 4-(3-((5-hydroxy-2-methylpentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylic acid tert-butyl ester

[0483] Under ice-water cooling, tert-butyl 4-(3-((5-ethoxy-2-methyl-5-oxopentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylate (9.57 g, 20 mmol) and anhydrous THF (200 mL) were added to a 500 mL single-mouth bottle equipped with a magnetic stirrer in sequence, stirred to dissolve, and LiAlH4 (0.76 g, 20 mmol) was slowly added. After the addition was completed, the reaction was stirred for 1 hour under a nitrogen atmosphere. Sodium sulfate decahydrate was slowly added until no bubbles were generated, the insoluble solid was filtered off, and the product was washed with ethyl acetate (50 mL). The filtrate was concentrated and passed through a silica gel column to obtain 7.2 g of a yellow oil with a yield of 82.5%. LC-MS (APCI): m / z=437.3 (M+1) + .

[0484] Step 4: Synthesis of Compound 4-(3-((2-methyl-5-((methylsulfonyl)oxy)pentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylic acid tert-butyl ester

[0485] Under ice-water cooling, tert-butyl 4-(3-((5-hydroxy-2-methylpentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylate (7.2 g, 16.5 mmol), triethylamine (2.5 g, 24.7 mmol) and anhydrous DCM (200 mL) were added in sequence to a 500 mL single-mouth bottle equipped with a magnetic stirrer, and methylsulfonyl chloride (18.15 mmol) was slowly added dropwise. After the addition, the ice bath was removed, and the reaction was stirred at room temperature under nitrogen for 2 hours. Water (100 mL) was added to quench the reaction, and the organic phase was separated. The aqueous phase was extracted with dichloromethane (80 mL), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and used directly in the next step.

[0486] Step 5: Synthesis of Compound 4-(3-((5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-methylpentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylic acid tert-butyl ester

[0487] DMF (80 mL) was added to a 250 mL single-necked bottle containing tert-butyl-(3-((2-methyl-5-((methylsulfonyl)oxy)pentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylate (about 16.5 mmol), stirred to dissolve, and intermediate F-1 (4.67 g, 16.5 mmol) and potassium carbonate (6.83 g, 49.5 mmol) were added. The temperature was raised to 60°C, and the reaction was stirred and kept warm overnight under nitrogen. After cooling to room temperature, ethyl acetate (200 mL) was added, insoluble solids were filtered out, and the filter cake was washed with ethyl acetate (50 mL). The organic phases were combined and concentrated to dryness under reduced pressure. The residue was passed through a silica gel column to obtain 7.8 g of a light yellow solid with a yield of 71.0%. LC-MS (APCI): m / z=666.7 (M+1) + , 1 H NMR (300MHz, CDCl3) δ (ppm): 8.23-8.18 (m, 1H), 8.12 (d, J = 9.2Hz, 1H), 7.87 (s, 1H), 7.86 (br s,1H),7.48(s,1H),6.80(s,1H),7.63(d,J=8.8Hz,1H),4.15(t,J=6.4H z,2H),3.94(s,3H),3.74(s,3H),3.45-3.41(m,7H),3.28-3.24(m,1H), 3.19-3.14(m,1H),2.61(s,3H),2.41-2.36(m,4H),2.01-1.92(m,2H),1 .90-1.85(m,2H),1.75-1.69(m,1H),1.45(s,9H),1.12(d,J=6.4Hz,3H).

[0488] Step 6: Synthesis of tert-butyl 4-(4-amino-3-((5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-methylpentyl)amino)benzyl)piperazine-1-carboxylate

[0489] To a 250 mL single-mouth bottle equipped with a magnetic stirrer, tert-butyl 4-(3-((5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-methylpentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylate (4.0 g, 6.0 mmol) and methanol (80 mL) were added, stirred to dissolve, Pt / C (1.2 g, 10%) was added, vacuum was evacuated and hydrogen was replaced three times, and the reaction was stirred at room temperature under a hydrogen balloon atmosphere for 2 hours. The catalyst was filtered off, washed with dichloromethane (20 mL), and the filtrate was concentrated to dryness to obtain 3.81 g of brown solid, with a yield of 100%, which was directly used in the next step. LC-MS (APCI): m / z=636.7 (M+1) + .

[0490] Step 7 Synthesis of Compound 4-((2-amino-1-(5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-methylpentyl)-1H-benzo[d]imidazol-6-yl)methyl)piperazine-1-carboxylic acid tert-butyl ester

[0491] Under ice-water bath, add 4-(4-amino-3-((5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-methylpentyl)amino)benzyl)piperazine-1-carboxylic acid tert-butyl ester (3.81g, 6.0mmol) and glacial acetic acid (80mL), stir to dissolve, slowly add solid cyanogen bromide (0.82g, 7.8mmol), after addition, remove the ice bath, stir and react at room temperature overnight under nitrogen atmosphere. Under ice-water bath, add ethyl acetate (150mL) and water (50mL) to quench the reaction, add ammonia water dropwise, adjust pH value to ~9, separate the organic phase, extract the aqueous phase with ethyl acetate (60mLx2), combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate to dryness, and pass the residue through a silica gel column to obtain 3.0g of off-white solid, with a yield of 75.7%. LC-MS (APCI): m / z = 661.7 (M+1) + .

[0492] Step 8 Synthesis of Compound 2-(5-((5-(2-amino-6-((4-(tert-butyloxycarbonyl)piperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-4-methylpentyl)oxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinic acid

[0493] To a 100 mL single-mouth bottle equipped with a magnetic stirrer, tert-butyl 4-((2-amino-1-(5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-methylpentyl)-1H-benzo[d]imidazol-6-yl)methyl)piperazine-1-carboxylate (3.0 g, 4.54 mmol), THF (20 mL) and water (20 mL) were added, stirred to dissolve, LiOH-H2O (0.38 g, 9.08 mmol) was added, and the reaction was stirred at room temperature for 2 hours under nitrogen. The organic solvent was evaporated under reduced pressure, cooled in an ice-water bath, and citric acid solid (0.58 g, 3.03 mmol) was slowly added to precipitate a large amount of white solid, which was filtered, the filter cake was washed with water (10 mL), and dried to obtain 2.2 g of white solid, with a yield of 74.9%. LC-MS (APCI): m / z = 647.7 (M+1) + .

[0494] Step 9 Compound (E)-4-((1 1 ,2 6 ,7-Trimethyl-3-oxo-5 2 ,5 3 -Dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-5-nitropropene 6 Synthesis of tert-butyl (-)methyl)piperazine-1-carboxylate

[0495] To a 100 mL single-necked bottle equipped with a magnetic stirrer, 2-(5-((5-(2-amino-6-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-4-methylpentyl)oxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinic acid (2.2 g, 3.4 mmol) and anhydrous dichloromethane (40 mL) were added, and the mixture was stirred to dissolve. DIPEA (0.88 g, 6.8 mmol) and TBTU (1.64 g, 5.1 mmol) were added. After the addition was complete, the reaction was stirred at room temperature under nitrogen for 2 hours. Dichloromethane (30 mL) was added to dilute the reaction solution, water (50 mL) was added, and the mixture was stirred for 5 minutes. The organic phase was separated, washed with dichloromethane and extracted (30 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel column to obtain 1.4 g of a light yellow solid, with a yield of 65.5%. LC-MS (APCI): m / z = 629.7 (M+1) + . 1H NMR (400MHz, CDCl3) δ (ppm): 11.99 (br s,1H),8.51(s,1H),8.18(s,1H),7.68(s,1H),7.34-7.32(m,1H),7.26-7.21(m,2H),4. 52-4.47(m,1H),4.41-4.34(m,1H),3.94-3.89(m,1H),3.81(s,3H),3.80-3.73(m,1H),3 .65(s,2H),3.54-3.41(m,4H),2.88-2.82(m,1H),2.67(s,3H),2.51-2.48(m,4H),2.32 -2.26(m,1H),2.20-1.13(m,1H),2.07-1.97(m,2H),1.55(s,9H),0.93(d,J=6.8Hz,3H).

[0496] Step 10 Compound (E)-1 1 ,2 6 ,7-Trimethyl-5 6 -(piperazin-1-ylmethyl)-5- 2 ,5 3 -Dihydro-1 1 H,5 1 Synthesis of H-11-oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-3-one

[0497] (E)-4-((1 1 ,2 6 ,7-Trimethyl-3-oxo-5 2 ,5 3 -Dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-5-nitropropene 6-yl)methyl)piperazine-1-carboxylic acid tert-butyl ester (1.4g, 2.23mmol) and 5M hydrochloric acid isopropanol solution (20mL) were stirred under nitrogen for 2 hours. Ethyl acetate (40mL) was added to precipitate a large amount of white solid, which was filtered and washed with ethyl acetate (10mL). Dichloromethane (20mL) and water (5mL) were added to the filter cake, and ammonia water was added dropwise to adjust the pH to 9. The organic phase was separated, washed with water and extracted with dichloromethane (10mLx3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness to obtain 0.9g of brown solid, with a yield of 76.3%, which was directly used in the next step. LC-MS (APCI): m / z=529.7 (M+1) + .

[0498] Step 11 Synthesis of Compound T-1

[0499] Add (E)-1 to a 50 mL single-necked bottle equipped with a magnetic stirrer. 1 ,2 6 ,7-Trimethyl-5 6 -(piperazin-1-ylmethyl)-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-3-one (0.9 g, 1.70 mmol) and methanol (15 mL) were stirred to dissolve, deuterated formaldehyde (0.54 g, 3.40 mmol, w / w 20% heavy aqueous solution) and glacial acetic acid (10 mg, 0.17 mmol) were added, and the mixture was stirred under nitrogen for 20 minutes, and sodium deuterated cyanoborohydride (0.17 g, 2.55 mmol) was added, and the mixture was stirred for 2 hours. Saturated brine (20 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel column to obtain 0.65 g of an off-white solid with a yield of 70.1%. LC-MS (APCI): m / z = 546.7 (M+1) + , 1H NMR (400MHz, CDCl3) δ (ppm): 11.94 (br s,1H),8.49(s,1H),8.16(s,1H),7.65(s,1H),7.31-7.27(m,2H),7.23-7.20(m,1H) ,4.51-4.45(m,1H),4.38-4.33(m,1H),3.92-3.87(m,1H),3.79(s,3H),3.76-3.71(m ,1H),3.62(s,2H),2.87-2.81(m,1H),2.64-2.42(m,8H),2.65(s,3H),2.26-2.23(m, 1H),2.15-2.06(m,1H),2.03-1.91(m,2H),1.54-1.46(m,2H),0.92(d,J=6.4Hz,3H).

[0500] Step 12 Synthesis of compounds T-1-R and T-1-S

[0501] The racemic compound T-1 (0.65 g) was dissolved in methanol (80 mL) and subjected to chiral preparative separation by SFC. The separation conditions were as follows:

[0502] Instrument: Waters SFC-150; chiral column: Daicel OD 20*250mm, 10um; mobile phase: CO2 / EtOH [0.5% NH3 (7M in MeOH)] = 70 / 30; flow rate: 100 g / min, column temperature: 35°C; column pressure: 100 bar; detection wavelength: 214 nm; cycle time: 6 min; injection volume: 4 mL.

[0503] The corresponding fractions were collected and dried by spin drying to obtain 300 mg of isomer T-1-R with a corresponding retention time of 2.948 min; and 300 mg of isomer T-1-S with a corresponding retention time of 3.553 min (wherein, the chiral analysis conditions were: HPLC, column: OD-34.6*100mm 3um; mobile phase: EtOH [1% NH3 (7M in MeOH)]; flow rate: 3.0 mL / min; column temperature: 40°C; pressure: 200 psi).

[0504] Example 2(E)-1 1 ,2 6 -Dimethyl-7-(methyl-d3)-5 6 -(piperazin-1-ylmethyl)-5- 2 ,5 3 -Dihydro-1 1 H, 5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecene- 3-Keto (Compound T-2);

[0505] (E)-1 1 ,2 6 -Dimethyl-7-(methyl-d3)-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3 -Dihydro-1 1 H, 5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecene- 3-Keto (Compound T-3);

[0506] (R,E)-1 1 ,2 6 -Dimethyl-7-(methyl-d3)-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3 -Dihydro- 1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecane Fen-3-one (compound T-3-R);

[0507] (S,E)-1 1 ,2 6 -Dimethyl-7-(methyl-d3)-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3 -Dihydro- 1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecane Preparation of fen-3-one (compound T-3-S)

[0508]

[0509] The following synthetic route was used

[0510]

[0511] Step 1 Synthesis of Compound 4-(3-((5-hydroxy-2-(methyl-d3)pentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylic acid tert-butyl ester

[0512] DMF (100 mL) was added to a 250 mL single-mouth bottle containing intermediate G-2 (about 48.4 mmol), potassium carbonate (16.7 g, 121 mmol) and tert-butyl 4-(3-fluoro-4-nitrobenzyl)piperazine-1-carboxylate (15.3 g, 45 mmol) were added under stirring, and the temperature was raised to 60°C under nitrogen, and the reaction was stirred overnight. After cooling to room temperature, the reaction solution was poured into dichloromethane (200 mL), the inorganic salt was filtered off, and the solution was washed with dichloromethane (50 mL). The filtrate was concentrated to dryness under reduced pressure and passed through a silica gel column to obtain 16.5 g of a yellow oil with a yield of 83.5%. LC-MS (APCI): m / z=440.5 (M+1) + .

[0513] Step 2 Synthesis of Compound 4-(3-((2-(methyl-d3)-5-((methylsulfonyl)oxy)pentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylic acid tert-butyl ester

[0514] Under ice-water cooling, tert-butyl 4-(3-((5-hydroxy-2-(methyl-d3)pentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylate (7.3 g, 16.5 mmol), triethylamine (2.5 g, 24.7 mmol) and anhydrous DCM (200 mL) were added in sequence to a 500 mL single-mouth bottle equipped with magnetic stirring, and methylsulfonyl chloride (18.15 mmol) was slowly added dropwise. After the dropwise addition, the ice bath was removed, and the reaction was stirred at room temperature under nitrogen for 2 hours. Water (100 mL) was added to quench the reaction, the organic phase was separated, the aqueous phase was extracted with dichloromethane (80 mL), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and used directly in the next step.

[0515] Step 3 Synthesis of Compound 4-(3-((5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-(methyl-d3)pentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylic acid tert-butyl ester

[0516] DMF (80 mL) was added to a 250 mL single-mouth bottle containing tert-butyl 4-(3-((2-(methyl-d3)-5-((methylsulfonyl)oxy)pentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylate (about 16.5 mmol), stirred to dissolve, and intermediate F-1 (4.67 g, 16.5 mmol) and potassium carbonate (6.83 g, 49.5 mmol) were added. The temperature was raised to 60°C, and the reaction was stirred and kept warm overnight under nitrogen. After cooling to room temperature, ethyl acetate (200 mL) was added, insoluble solids were filtered off, and the filter cake was washed with ethyl acetate (50 mL). The organic phases were combined and concentrated to dryness under reduced pressure. The residue was passed through a silica gel column to obtain 8.2 g of a light yellow solid with a yield of 74.3%. LC-MS (APCI): m / z=669.4 (M+1) + , 1 H NMR (300MHz, CDCl3) δ (ppm): 8.23-8.18 (m, 1H), 8.12 (d, J = 9.2Hz, 1H), 7.87 (s, 1H), 7.86 (br s,1H),7.48(s,1H),6.80(s,1H),7.63(d,J=8.8Hz,1H),4.15(t,J=6.4Hz,2H),3.94(s,3H),3.74(s,3H),3.45-3.41(m,7H),3.28-3. 24(m,1H),3.19-3.14(m,1H),2.61(s,3H),2.41-2.36(m,4H),2.01-1.92(m,2H),1.90-1.85(m,2H),1.75-1.69(m,1H),1.45(s,9H).

[0517] Step 4: Synthesis of tert-butyl 4-(4-amino-3-((5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-(methyl-d3)pentyl)amino)benzyl)piperazine-1-carboxylate

[0518] To a 250 mL single-mouth bottle equipped with a magnetic stirrer, tert-butyl 4-(3-((5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-(methyl-d3)pentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylate (4.0 g, 6.0 mmol) and methanol (80 mL) were added, stirred to dissolve, Pt / C (1.2 g, 10%) was added, vacuumed and replaced with hydrogen three times, and stirred at room temperature under a hydrogen balloon atmosphere for 2 hours. The catalyst was filtered off, washed with dichloromethane (20 mL), and the filtrate was concentrated to dryness to obtain 3.81 g of a brown solid with a yield of 100%, which was directly used in the next step. LC-MS (APCI): m / z=640.0 (M+1) + .

[0519] Step 5 Synthesis of Compound 4-((2-amino-1-(5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-(methyl-d3)pentyl)-1H-benzo[d]imidazol-6-yl)methoxy)piperazine-1-carboxylic acid tert-butyl ester

[0520] Under an ice-water bath, to a 100 mL single-necked bottle charged with tert-butyl 4-(4-amino-3-((5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-(methyl-(3)pentyl)amino)benzyl)piperazine-1-carboxylate (3.81 g, 6.0 mmol) was added glacial acetic acid (80 mL), stirred to dissolve, and solid cyanogen bromide (0.82 g, 7.8 mmol) was slowly added. After the addition was complete, the ice bath was removed and the reaction was stirred at room temperature under nitrogen overnight. Under ice-water bath, ethyl acetate (150 mL) and water (50 mL) were added to quench the reaction, and aqueous ammonia was added dropwise to adjust the pH value to 9, the organic phase was separated, the aqueous phase was extracted with ethyl acetate (60 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and the residue was passed through a silica gel column to obtain 3.3 g of an off-white solid, with a yield of 82.8%. LC-MS (APCI): m / z = 664.7 (M+1) + .

[0521] Step 6 Synthesis of Compound 2-(5-((4-((2-amino-6-((4-(tert-butyloxycarbonyl)piperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)methyl)pentyl-5,5,5-d3)oxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinic acid

[0522] To a 100 mL single-mouth bottle equipped with a magnetic stirrer, tert-butyl 4-((2-amino-1-(5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-(methyl-d3)pentyl)-1H-benzo[d]imidazol-6-yl)methoxy)piperazine-1-carboxylate (3.2 g, 4.82 mmol), THF (20 mL) and water (20 mL) were added, stirred to dissolve, LiOH-H2O (0.38 g, 9.08 mmol) was added, and the reaction was stirred at room temperature for 2 hours under nitrogen. The organic solvent was evaporated under reduced pressure, cooled in an ice-water bath, and citric acid solid (0.58 g, 3.03 mmol) was slowly added to precipitate a large amount of white solid, which was filtered, the filter cake was washed with water (10 mL), and dried to obtain 2.3 g of white solid, with a yield of 73.4%. LC-MS (APCI): m / z = 650.7 (M+1) + .

[0523] Step 7 Compound (E)-4-((1 1 ,2 6 -Dimethyl-7-(methyl-d3)-3-oxo-5 2 ,5 3 -Dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-5-nitropropene 6 Synthesis of tert-butyl (-)methyl)piperazine-1-carboxylate

[0524] To a 100 mL single-necked bottle equipped with a magnetic stirrer, 2-(5-((4-((2-amino-6-((4-(tert-butyloxycarbonyl)piperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)methyl)pentyl-5,5,5-d3)oxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinic acid (2.2 g, 3.4 mmol) and anhydrous dichloromethane (40 mL) were added, stirred to dissolve, DIPEA (0.88 g, 6.8 mmol) and TBTU (1.64 g, 5.1 mmol) were added, and the reaction was stirred at room temperature under nitrogen for 2 hours. Dichloromethane (30 mL) was added to dilute the reaction solution, water (50 mL) was added, and the mixture was stirred for 5 minutes. The organic phase was separated, washed with dichloromethane and extracted (30 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel column to obtain 1.4 g of a light yellow solid, with a yield of 65.5%. LC-MS (APCI): m / z = 632.7 (M+1) + .

[0525] Step 8 Synthesis of Compound T-2

[0526] (E)-4-((1 1 ,2 6 -Dimethyl-7-(methyl-d3)-3-oxo-5 2 ,5 3 -Dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-5-nitropropene 6 -yl)methyl)piperazine-1-carboxylic acid tert-butyl ester (1.4g, 2.22mmol) and 5M hydrochloric acid isopropanol solution (20mL) were stirred under nitrogen for 2 hours. Ethyl acetate (40mL) was added to precipitate a large amount of white solid, which was filtered and washed with ethyl acetate (10mL). Dichloromethane (20mL) and water (5mL) were added to the filter cake, and ammonia water was added dropwise to adjust the pH to 9. The organic phase was separated, washed with water, extracted with dichloromethane (10mLx3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness to obtain 0.9g of brown solid, with a yield of 76.3%, which was directly used in the next step. LC-MS (APCI): m / z=532.7 (M+1) + .

[0527] Step 9 Synthesis of Compound T-3

[0528] Compound T-2 (0.45 g, 0.85 mmol) and methanol (8 mL) were added to a 50 mL single-mouth bottle equipped with a magnetic stirrer, stirred to dissolve, formaldehyde (0.27 g, 1.7 mmol, w / w 20% solution) and glacial acetic acid (5 mg, 0.08 mmol) were added, stirred under nitrogen for 20 minutes, sodium cyanoborohydride (80 mg, 1.25 mmol) was added, and the stirring reaction was continued for 2 hours. Saturated brine (20 mL) was added to quench the reaction, and ethyl acetate was extracted (30 mL x 3), the organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and the residue was passed through a silica gel column to obtain 0.35 g of an off-white solid with a yield of 75.4%. LC-MS (APCI): m / z = 546.7 (M+1) +, 1H NMR (400MHz, CDCl3) δ (ppm): 11.94 (br s,1H),8.49(s,1H),8.16(s,1H),7.65(s,1H),7.31-7.27(m,2H),7.23-7.20(m,1 H),4.51-4.45(m,1H),4.38-4.33(m,1H),3.92-3.87(m,1H),3.79(s,3H),3.76-3. 71(m,1H),3.62(s,2H),2.87-2.81(m,1H),2.64-2.42(m,8H),2.65(s,3H),2.33(s ,3H),2.26-2.23(m,1H),2.15-2.06(m,1H),2.03-1.91(m,2H),1.54-1.46(m,2H).

[0529] Step 10 Synthesis of compounds T-3-R and T-3-S

[0530] The racemic compound T-3 (0.35 g) was dissolved in methanol (40 mL) and subjected to chiral preparative separation by SFC. The separation conditions were as follows:

[0531] Instrument: Waters SFC-150; chiral column: Daicel OD 20*250mm, 10um; mobile phase: CO2 / EtOH [0.5% NH3 (7M in MeOH)] = 70 / 30; flow rate: 100 g / min, column temperature: 35°C; column pressure: 100 bar; detection wavelength: 214 nm; cycle time: 6 min; injection volume: 4 mL.

[0532] The corresponding fractions were collected and dried by spin drying to obtain 150 mg of isomer T-3-R with a corresponding retention time of 2.948 min; and 150 mg of isomer T-3-S with a retention time of 3.553 min (wherein, the chiral analysis conditions were: HPLC, column: OD-3 4.6*100mm 3um; mobile phase: EtOH [1% NH3 (7M in MeOH)]; flow rate: 3.0 mL / min; column temperature: 40°C; pressure: 200 psi).

[0533] Example 3(E)-1 1 ,2 6 -Dimethyl-7-(methyl-d3)-5 6 -((4-(methyl-d3)piperazin-1-yl)methyl)-5-(4-(methyl-d3)piperazin-1-yl)methyl)- 2 , 5 3 -Dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazole Cyclododecaphen-3-one (compound T-4);

[0534] (R,E)-(E)-1 1 ,2 6 -Dimethyl-7-(methyl-d3)-5 6 -((4-(methyl-d3)piperazin-1-yl)methyl)-5-(4-(methyl-d3)piperazin-1-yl)methyl)- 2 , 5 3 -Dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazole Cyclododecaphen-3-one (compound T-4-R);

[0535] (S,E)-(E)-1 1 ,2 6 -Dimethyl-7-(methyl-d3)-5 6 -((4-(methyl-d3)piperazin-1-yl)methyl)-5-(4-(methyl-d3)piperazin-1-yl)methyl)- 2 , 5 3 -Dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazole Preparation of cyclododecaphen-3-one (compound T-4-S)

[0536]

[0537] The following synthetic route was used

[0538]

[0539] Step 1 Synthesis of Compound T-4

[0540] Compound T-2 (0.45 g, 0.85 mmol) and methanol (8 mL) were added to a 50 mL single-mouth bottle equipped with a magnetic stirrer, stirred to dissolve, deuterated formaldehyde (0.27 g, 1.7 mmol, w / w 20% heavy aqueous solution) and glacial acetic acid (5 mg, 0.08 mmol), stirred for 20 minutes under a nitrogen atmosphere, and sodium deuterated cyanoborohydride (80 mg, 1.25 mmol) was added, and the stirring reaction continued for 2 hours. Saturated brine (20 mL) was added to quench the reaction, and ethyl acetate was extracted (30 mL x 3), the organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and the residue was passed through a silica gel column to obtain 0.35 g of an off-white solid with a yield of 75.4%. LC-MS (APCI): m / z = 546.7 (M+1) + , 1 H NMR (400MHz, CDCl3) δ (ppm): 11.94 (br s,1H),8.49(s,1H),8.16(s,1H),7.65(s,1H),7.31-7.27(m,2H),7.23-7.20(m ,1H),4.51-4.45(m,1H),4.38-4.33(m,1H),3.92-3.87(m,1H),3.79(s,3H),3. 76-3.71(m,1H),3.62(s,2H),2.87-2.81(m,1H),2.64-2.42(m,8H),2.65(s,3H ),2.26-2.23(m,1H),2.15-2.06(m,1H),2.03-1.91(m,2H),1.54-1.46(m,2H).

[0541] Step 2 Synthesis of compounds T-4-R and T-4-S

[0542] The racemic compound T-4 (0.35 g) was dissolved in methanol (40 mL) and subjected to chiral preparative separation by SFC. The separation conditions were as follows:

[0543] Instrument: Waters SFC-150; chiral column: Daicel OD 20*250mm, 10um; mobile phase: CO2 / EtOH [0.5% NH3 (7M in MeOH)] = 70 / 30; flow rate: 100 g / min, column temperature: 35°C; column pressure: 100 bar; detection wavelength: 214 nm; cycle time: 6 min; injection volume: 4 mL.

[0544] The corresponding fractions were collected and dried to give 145 mg of isomer T-4-R with a corresponding retention time of 2.948 min; and 148 mg of isomer T-4-S with a retention time of 3.553 min (wherein, the chiral analysis conditions were: HPLC, column: OD-3 4.6*100mm 3um; mobile phase: EtOH [1% NH3 (7M in MeOH)]; flow rate: 3.0 mL / min; column temperature: 40°C; pressure: 200 psi).

[0545] Example 4(E)-2 6 ,7-dimethyl-1 1 -(methyl-d3)-5 6 -(piperazin-1-ylmethyl)-5- 2 ,5 3 -Dihydro-1 1 H, 5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecene- 3-Keto (Compound T-5)

[0546] (E)-2 6 ,7-dimethyl-1 1 -(methyl-d3)-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3 -Dihydro-1 1 H, 5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecene- 3-Keto (Compound T-6);

[0547] (R,E)-2 6 ,7-dimethyl-1 1 -(methyl-d3)-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3 -Dihydro- 1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecane Fen-3-one (compound T-6-R);

[0548] (S,E)-2 6 ,7-dimethyl-1 1 -(methyl-d3)-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3 -Dihydro- 1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecane Preparation of fen-3-one (compound T-6-S)

[0549]

[0550] The following synthetic route was used

[0551]

[0552] Step 1 Synthesis of tert-butyl 4-(3-((5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-(methyl-d3)-1H-pyrazol-5-yl)oxy)-2-methylpentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylate

[0553] DMF (30 mL) was added to a 100 mL single-necked bottle containing tert-butyl (3-((2-methyl-5-((methylsulfonyl)oxy)pentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylate (about 9.38 mmol), stirred to dissolve, and intermediate F-2 (2.69 g, 9.38 mmol) and potassium carbonate (3.88 g, 28.0 mmol) were added. The temperature was raised to 60°C, and the reaction was stirred and kept warm overnight under nitrogen. After cooling to room temperature, ethyl acetate (100 mL) was added, insoluble solids were filtered off, and the filter cake was washed with ethyl acetate (50 mL). The organic phases were combined and concentrated to dryness under reduced pressure. The residue was passed through a silica gel column to obtain 4.78 g of a light yellow solid with a yield of 76.2%. LC-MS (APCI): m / z=669.4 (M+1) + .

[0554] Step 2 Synthesis of compound 4-(4-amino-3-((5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-(methyl-d3)-1H-pyrazol-5-yl)oxy)-2-methylpentyl)amino)benzyl)piperazine-1-carboxylic acid tert-butyl ester

[0555] To a 100 mL single-mouth bottle equipped with a magnetic stirrer, add tert-butyl 4-(3-((5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-(methyl-d3)-1H-pyrazol-5-yl)oxy)-2-methylpentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylate (4.0 g, 6.0 mmol) and methanol (80 mL), stir to dissolve, add Pt / C (1.2 g, 10%), evacuate and replace with hydrogen three times, stir at room temperature under hydrogen balloon atmosphere for 2 hours. Filter out the catalyst, wash with dichloromethane (20 mL), and concentrate the filtrate to dryness to obtain 3.81 g of brown solid with a yield of 100%, which is directly used in the next step. LC-MS (APCI): m / z=639.5 (M+1) + .

[0556] Step 3 Synthesis of Compound 4-((2-amino-1-(5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-(methyl-d3)-1H-pyrazol-5-yl)oxy)-2-methylpentyl)-1H-benzo[d]imidazol-6-yl)methyl)piperazine-1-carboxylic acid tert-butyl ester

[0557] Under ice-water bath, to a 100mL single-necked bottle charged with tert-butyl 4-(4-amino-3-((5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-(methyl-d3)-1H-pyrazol-5-yl)oxy)-2-methylpentyl)amino)benzyl)piperazine-1-carboxylate (3.81 g, 6.0 mmol) was added glacial acetic acid (40 mL), stirred to dissolve, and solid cyanogen bromide (0.82 g, 7.8 mmol) was slowly added. After the addition was complete, the ice bath was removed and the reaction was stirred at room temperature under nitrogen overnight. Under ice-water bath, ethyl acetate (150 mL) and water (50 mL) were added to quench the reaction, and aqueous ammonia was added dropwise to adjust the pH value to 9. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (60 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel column to obtain 3.5 g of an off-white solid with a yield of 87.9%. LC-MS (APCI): m / z = 664.7 (M+1) + .

[0558] Step 4: Synthesis of Compound 2-(5-((5-(2-amino-6-((4-(tert-butyloxycarbonyl)piperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-4-methylpentyl)oxy)-1-(methyl-d3)-1H-pyrazol-4-yl)-6-methylisonicotinic acid

[0559] To a 100 mL single-mouth bottle equipped with a magnetic stirrer, tert-butyl 4-((2-amino-1-(5-((4-(4-(methoxycarbonyl)-6-methylpyridin-2-yl)-1-(methyl-d3)-1H-pyrazol-5-yl)oxy)-2-methylpentyl)-1H-benzo[d]imidazol-6-yl)methyl)piperazine-1-carboxylate (3.2 g, 4.82 mmol), THF (20 mL) and water (20 mL) were added, stirred to dissolve, LiOH-H2O (0.38 g, 9.08 mmol) was added, and the reaction was stirred at room temperature for 2 hours under nitrogen. The organic solvent was evaporated under reduced pressure, cooled in an ice-water bath, and citric acid solid (0.58 g, 3.03 mmol) was slowly added to precipitate a large amount of white solid, which was filtered, the filter cake was washed with water (10 mL), and dried to obtain 2.2 g of white solid, with a yield of 70.2%. LC-MS (APCI): m / z = 650.7 (M+1) + .

[0560] Step 5 Compound (E)-4-((2 6 ,7-dimethyl-1 1 -(Methyl-d3)-3-oxo-5- 2 ,5 3 -Dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-5-nitropropene 6 Synthesis of tert-butyl (-)methyl)piperazine-1-carboxylate

[0561] To a 100 mL single-necked bottle equipped with a magnetic stirrer, 2-(5-((5-(2-amino-6-((4-(tert-butyloxycarbonyl)piperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-4-methylpentyl)oxy)-1-(methyl-d3)-1H-pyrazol-4-yl)-6-methylisonicotinic acid (2.2 g, 3.4 mmol) and anhydrous dichloromethane (40 mL) were added, and the solution was stirred to dissolve. DIPEA (0.88 g, 6.8 mmol) and TBTU (1.64 g, 5.1 mmol) were added. After the addition was complete, the reaction was stirred at room temperature under nitrogen for 2 hours. Dichloromethane (30 mL) was added to dilute the reaction solution, water (50 mL) was added, and the mixture was stirred for 5 minutes. The organic phase was separated, washed with dichloromethane extract (30 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel column to obtain 1.5 g of a light yellow solid, with a yield of 69.8%. LC-MS (APCI): m / z = 632.7 (M+1) + .

[0562] Step 6 Synthesis of Compound T-5

[0563] (E)-4-((2 6 ,7-dimethyl-1 1 -(Methyl-d3)-3-oxo-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-5-nitropropene 6 -yl)methyl)piperazine-1-carboxylic acid tert-butyl ester (1.4g, 2.22mmol) and 5M hydrochloric acid isopropanol solution (20mL) were stirred under nitrogen for 2 hours. Ethyl acetate (40mL) was added to precipitate a large amount of white solid, which was filtered and washed with ethyl acetate (10mL). Dichloromethane (20mL) and water (5mL) were added to the filter cake, and ammonia water was added dropwise to adjust the pH to 9. The organic phase was separated, washed with water, extracted with dichloromethane (10mLx3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness to obtain 0.91g of brown solid, with a yield of 77.1%, which was directly used in the next step. LC-MS (APCI): m / z=532.7 (M+1) + .

[0564] Step 7 Synthesis of Compound T-6

[0565] Compound T-5 (0.45 g, 0.85 mmol) and methanol (8 mL) were added to a 50 mL single-mouth bottle equipped with a magnetic stirrer, stirred to dissolve, formaldehyde (0.27 g, 1.7 mmol, w / w 20% solution) and glacial acetic acid (5 mg, 0.08 mmol) were added, stirred and reacted for 20 minutes under nitrogen, sodium cyanoborohydride (80 mg, 1.25 mmol) was added, and the stirring reaction was continued for 2 hours. Saturated brine (20 mL) was added to quench the reaction, and ethyl acetate was extracted (30 mL x 3), the organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and the residue was passed through a silica gel column to obtain 0.36 g of an off-white solid with a yield of 77.6%. LC-MS (APCI): m / z=546.7 (M+1) + , 1 H NMR (400MHz, CDCl3) δ (ppm): 11.94 (br s,1H),8.49(s,1H),8.16(s,1H),7.65(s,1H),7.31-7.27(m,2H),7.23-7.20(m,1H) ,4.51-4.45(m,1H),4.38-4.33(m,1H),3.92-3.87(m,1H),3.76-3.71(m,1H),3.62(s ,2H),2.87-2.81(m,1H),2.64-2.42(m,8H),2.65(s,3H),2.33(s,3H),2.26-2.23(m, 1H),2.15-2.06(m,1H),2.03-1.91(m,2H),1.54-1.46(m,2H),0.92(d,J=6.4Hz,3H).

[0566] Step 8 Synthesis of compounds T-6-R and T-6-S

[0567] The racemic compound T-6 (0.35 g) was dissolved in methanol (40 mL) and subjected to chiral preparative separation by SFC. The separation conditions were as follows:

[0568] Instrument: Waters SFC-150; chiral column: Daicel OD 20*250mm, 10um; mobile phase: CO2 / EtOH [0.5% NH3 (7M in MeOH)] = 70 / 30; flow rate: 100 g / min, column temperature: 35°C; column pressure: 100 bar; detection wavelength: 214 nm; cycle time: 6 min; injection volume: 4 mL.

[0569] The corresponding fractions were collected and dried to give 150 mg of isomer T-6-R with a corresponding retention time of 2.948 min; and 150 mg of isomer T-6-S with a retention time of 3.553 min (wherein, the chiral analysis conditions were: HPLC, column: OD-3 4.6*100mm 3um; mobile phase: EtOH [1% NH3 (7M in MeOH)]; flow rate: 3.0 mL / min; column temperature: 40°C; pressure: 200 psi).

[0570] Example 5(E)-2 6 ,7-dimethyl-1 1 -(methyl-d3)-5 6 -((4-(methyl-d3)piperazin-1-yl)methyl)-5-(4-(methyl-d3)piperazin-1-yl)methyl)- 2 , 5 3 -Dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazole Cyclododecaphen-3-one (compound T-7);

[0571] (R,E)-2 6 ,7-dimethyl-1 1 -(methyl-d3)-5 6 -((4-(methyl-d3)piperazin-1-yl)methyl)-5-(4-(methyl-d3)piperazin-1-yl)methyl)- 2 ,5 3 -two Hydrogen-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclodecane Difen-3-one (compound T-7-R);

[0572] (S,E)-2 6 ,7-dimethyl-1 1 -(methyl-d3)-5 6 -((4-(methyl-d3)piperazin-1-yl)methyl)-5-(4-(methyl-d3)piperazin-1-yl)methyl)- 2 ,5 3 -two Hydrogen-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclodecane Preparation of difen-3-one (compound T-7-S)

[0573]

[0574] The following synthetic route was used

[0575]

[0576] Step 1 Synthesis of compound T-7

[0577] Compound T-5 (0.45 g, 0.85 mmol) and methanol (8 mL) were added to a 50 mL single-mouth bottle equipped with a magnetic stirrer, stirred to dissolve, deuterated formaldehyde (0.27 g, 1.7 mmol, w / w 20% heavy aqueous solution) and glacial acetic acid (5 mg, 0.08 mmol), stirred for 20 minutes under a nitrogen atmosphere, and sodium deuterated cyanoborohydride (80 mg, 1.25 mmol) was added, and the stirring reaction continued for 2 hours. Saturated brine (20 mL) was added to quench the reaction, and ethyl acetate was extracted (30 mL x 3), the organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and the residue was passed through a silica gel column to obtain 0.35 g of an off-white solid with a yield of 75.4%. LC-MS (APCI): m / z = 546.7 (M+1) + , 1H NMR (400MHz, CDCl3) δ (ppm): 11.94 (br s,1H),8.49(s,1H),8.16(s,1H),7.65(s,1H),7.31-7.27(m,2H),7.23-7.20(m,1 H),4.51-4.45(m,1H),4.38-4.33(m,1H),3.92-3.87(m,1H),3.76-3.71(m,1H),3 .62(s,2H),2.87-2.81(m,1H),2.64-2.42(m,8H),2.65(s,3H),2.26-2.23(m,1H) ,2.15-2.06(m,1H),2.03-1.91(m,2H),1.54-1.46(m,2H),0.92(d,J=6.4Hz,3H).

[0578] Step 2 Synthesis of Compound T-7-R and Compound T-7-S

[0579] The racemic compound T-7 (0.35 g) was dissolved in methanol (40 mL) and subjected to chiral preparative separation by SFC. The separation conditions were as follows:

[0580] Instrument: Waters SFC-150; chiral column: Daicel OD 20*250mm, 10um; mobile phase: CO2 / EtOH [0.5% NH3 (7M in MeOH)] = 70 / 30; flow rate: 100 g / min, column temperature: 35°C; column pressure: 100 bar; detection wavelength: 214 nm; cycle time: 6 min; injection volume: 4 mL.

[0581] The corresponding fractions were collected and dried by spin drying to obtain 145 mg of isomer T-7-R with a corresponding retention time of 2.948 min; and 148 mg of isomer T-7-S with a corresponding retention time of 3.553 min (wherein, the chiral analysis conditions were: HPLC, column: OD-34.6*100mm 3um; mobile phase: EtOH [1% NH3 (7M in MeOH)]; flow rate: 3.0 mL / min; column temperature: 40°C; pressure: 200 psi).

[0582] Example 6(E)-1 1 ,7-dimethyl-2 6 -(methyl-d3)-5 6 -(piperazin-1-ylmethyl)-5- 2 ,5 3 -Dihydro-1 1 H, 5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecene- 3-Keto (Compound T-8);

[0583] (E)-1 1 ,7-dimethyl-2 6 -(methyl-d3)-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3 -Dihydro-1 1 H, 5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecene- 3-Keto (Compound T-9);

[0584] (R, E)-1 1 ,7-dimethyl-2 6 -(methyl-d3)-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3 -Dihydro- 1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecane Fen-3-one (compound T-9-R);

[0585] (S,E)-1 1 ,7-dimethyl-2 6 -(methyl-d3)-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3 -Dihydro- 1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecane Preparation of fen-3-one (compound T-9-S)

[0586]

[0587] The following synthetic route was used

[0588]

[0589] Step 1 Synthesis of Compound 4-(3-((5-((4-(4-(methoxycarbonyl)-6-(methyl-d3)pyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-methylpentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylic acid tert-butyl ester

[0590] DMF (10 mL) was added to a 50 mL single-mouth bottle containing tert-butyl 4-(3-((2-methyl-5-((methylsulfonyl)oxy)pentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylate (about 3.49 mmol), stirred to dissolve, and intermediate F-3 (1.0 g, 3.49 mmol) and potassium carbonate (1.44 g, 10.46 mmol) were added. The temperature was raised to 60°C, and the reaction was stirred and kept warm overnight under nitrogen. After cooling to room temperature, ethyl acetate (100 mL) was added, insoluble solids were filtered off, and the filter cake was washed with ethyl acetate (50 mL). The organic phases were combined and concentrated to dryness under reduced pressure. The residue was passed through a silica gel column to obtain 1.77 g of a light yellow solid with a yield of 75.8%. LC-MS (APCI): m / z=669.4 (M+1) + .

[0591] Step 2 Synthesis of Compound 4-(4-amino-3-((5-((4-(4-(methoxycarbonyl)-6-(methyl-d3)pyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-methylpentyl)amino)benzyl)piperazine-1-carboxylic acid tert-butyl ester

[0592] To a 100 mL single-necked bottle equipped with a magnetic stirrer, tert-butyl 4-(3-((5-((4-(4-(methoxycarbonyl)-6-(methyl-d3)pyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-methylpentyl)amino)-4-nitrobenzyl)piperazine-1-carboxylate (1.7 g, 2.54 mmol) and methanol (30 mL) were added, stirred to dissolve, Pt / C (0.51 g, 10%) was added, vacuumed and replaced with hydrogen three times, and stirred at room temperature under a hydrogen balloon atmosphere for 2 hours. The catalyst was filtered off, washed with dichloromethane (20 mL), and the filtrate was concentrated to dryness to obtain 1.7 g of a brown solid with a yield of 100%, which was directly used in the next step. LC-MS (APCI): m / z=639.5 (M+1) + .

[0593] Step 3 Synthesis of Compound 4-((2-amino-1-(5-((4-(4-(methoxycarbonyl)-6-(methyl-d3)pyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-methylpentyl)-1H-benzo[d]imidazol-6-yl)methyl)piperazine-1-carboxylic acid tert-butyl ester

[0594] Under an ice-water bath, to a 100 mL single-necked bottle charged with tert-butyl 4-(4-amino-3-((5-((4-(4-(methoxycarbonyl)-6-(methyl-d3)pyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-methylpentyl)amino)benzyl)piperazine-1-carboxylate (1.7 g, 2.54 mmol) was added glacial acetic acid (20 mL), stirred until dissolved, and solid cyanogen bromide (0.32 g, 3.05 mmol) was slowly added. After the addition was complete, the ice bath was removed and the reaction was stirred at room temperature overnight under a nitrogen atmosphere. Under ice-water bath, ethyl acetate (60 mL) and water (20 mL) were added to quench the reaction, and aqueous ammonia was added dropwise to adjust the pH value to 9, the organic phase was separated, the aqueous phase was extracted with ethyl acetate (40 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and the residue was passed through a silica gel column to obtain an off-white solid of 1.34 g, with a yield of 79.6%. LC-MS (APCI): m / z = 664.7 (M+1) + .

[0595] Step 4: Synthesis of compound 2-(5-((5-(2-amino-6-((4-(tert-butyloxycarbonyl)piperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-4-methylpentyl)oxy)-1-methyl-1H-pyrazol-4-yl)-6-(methyl-d3)isonicotinic acid

[0596] To a 100 mL single-mouth bottle equipped with a magnetic stirrer, tert-butyl 4-((2-amino-1-(5-((4-(4-(methoxycarbonyl)-6-(methyl-d3)pyridin-2-yl)-1-methyl-1H-pyrazol-5-yl)oxy)-2-methylpentyl)-1H-benzo[d]imidazol-6-yl)methyl)piperazine-1-carboxylate (1.3 g, 1.96 mmol), THF (15 mL) and water (15 mL) were added, stirred to dissolve, LiOH-H2O (0.16 g, 3.92 mmol) was added, and the reaction was stirred at room temperature for 2 hours under nitrogen. The organic solvent was evaporated under reduced pressure, cooled in an ice-water bath, and citric acid solid (0.25 g, 1.31 mmol) was slowly added to precipitate a large amount of white solid, which was filtered, the filter cake was washed with water (10 mL), and dried to obtain 0.83 g of white solid, with a yield of 65.5%. LC-MS (APCI): m / z = 650.7 (M+1) + .

[0597] Step 5 Compound (E)-4-((1 1 ,7-dimethyl-2 6 -(Methyl-d3)-3-oxo-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-5-nitropropene 6 Synthesis of tert-butyl (-)methyl)piperazine-1-carboxylate

[0598] To a 100 mL single-necked bottle equipped with a magnetic stirrer, 2-(5-((5-(2-amino-6-((4-(tert-butyloxycarbonyl)piperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-4-methylpentyl)oxy)-1-methyl-1H-pyrazol-4-yl)-6-(methyl-d3)isonicotinic acid (0.8 g, 1.23 mmol) and anhydrous dichloromethane (15 mL) were added, stirred to dissolve, DIPEA (0.32 g, 2.46 mmol) and TBTU (0.59 g, 1.84 mmol) were added, and the reaction was stirred at room temperature under a nitrogen atmosphere for 2 hours. Dichloromethane (30 mL) was added to dilute the reaction solution, water (50 mL) was added, and the mixture was stirred for 5 minutes. The organic phase was separated, washed with dichloromethane and extracted (30 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was passed through a silica gel column to obtain 0.53 g of a light yellow solid, with a yield of 68.2%. LC-MS (APCI): m / z = 632.7 (M+1) + .

[0599] Step 6 Synthesis of compound T-8

[0600] (E)-4-((1 1 ,7-dimethyl-2 6 -(Methyl-d3)-3-oxo-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-5-nitropropene 6 -yl)methyl)piperazine-1-carboxylic acid tert-butyl ester (0.53g, 0.84mmol) and ethyl acetate (2mL) were added, 5M hydrochloric acid isopropanol solution (10mL) was added, and the reaction was stirred for 2 hours under nitrogen. Ethyl acetate (40mL) was added to precipitate a large amount of white solid, which was filtered and washed with ethyl acetate (10mL). Dichloromethane (20mL) and water (5mL) were added to the filter cake, and ammonia water was added dropwise to adjust the pH to 9. The organic phase was separated, washed with water, extracted with dichloromethane (10mLx3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness to obtain 0.31g of brown solid, with a yield of 69.4%, which was directly used in the next step. LC-MS (APCI): m / z=532.7 (M+1) + .

[0601] Step 7 Synthesis of Compound T-9

[0602] Compound T-8 (0.3 g, 0.56 mmol) and methanol (8 mL) were added to a 50 mL single-mouth bottle equipped with a magnetic stirrer, stirred to dissolve, formaldehyde (0.18 g, 1.18 mmol, w / w 20% solution) and glacial acetic acid (3 mg, 0.05 mmol) were added, stirred under nitrogen for 20 minutes, sodium cyanoborohydride (53 mg, 0.84 mmol) was added, and the stirring reaction was continued for 2 hours. Saturated brine (20 mL) was added to quench the reaction, and ethyl acetate was extracted (30 mL x 3), the organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and the residue was passed through a silica gel column to obtain 0.22 g of an off-white solid with a yield of 72.0%.

[0603] Step 8 Synthesis of compounds T-9-R and T-9-S

[0604] The racemic compound T-9 (0.22 g) was dissolved in methanol (30 mL) and subjected to chiral preparative separation by SFC. The separation conditions were as follows:

[0605] Instrument: Waters SFC-150; chiral column: Daicel OD 20*250mm, 10um; mobile phase: CO2 / EtOH [0.5% NH3 (7M in MeOH)] = 70 / 30; flow rate: 100 g / min, column temperature: 35°C; column pressure: 100 bar; detection wavelength: 214 nm; cycle time: 6 min; injection volume: 4 mL.

[0606] The corresponding fractions were collected and dried by spin drying to obtain 150 mg of isomer T-9-R with a corresponding retention time of 2.948 min; and 150 mg of isomer T-9-S with a corresponding retention time of 3.553 min (wherein, the chiral analysis conditions were: HPLC, column: OD-34.6*100mm 3um; mobile phase: EtOH [1% NH3 (7M in MeOH)]; flow rate: 3.0 mL / min; column temperature: 40°C; pressure: 200 psi).

[0607] Biological activity testing.

[0608] (1) Wild-type EGFR and mutant EGFR kinase activity inhibition test

[0609] The inhibitory activity of the test drugs on EGFR WT, EGFRdel19, EGFR L858R, EGFR del19 T790M, EGFR L858R T790M, EGFR del19 T790M C797S and EGFR L858R T790M C797S (SignalChem, E-10-132GG) kinases was determined using the HTRF KinEASE-TK kit (Cisbio, 62TK0PEC).

[0610] The highest concentration of the drug to be tested was 1 μM, and the solution was diluted 3 times to 12 concentrations, and DMSO was used to prepare a 100× gradient solution. After 40× dilution with 1× kinase buffer, 4 μL of drug solution of various concentrations and 4 μL of substrate and ATP were added to each well of a 384-well plate (Perkin Elmer, 6008280), and mixed with 2 μL EGFR WT, 2 μL EGFR del19, 2 μL EGFRL858R, 2 μL EGFR del19 T790M, 2 μL EGFR L858R T790M, 2 μL EGFR del19 T790M C797S or 2 μL EGFR L858R T790M C797S, respectively, in duplicate wells, 1% DMSO was used as a positive control, and the well without kinase was used as a negative control, and incubated at 25°C for 20-60 minutes. The final detection concentration and action time of kinase, substrate, and ATP were determined after optimization of each kinase, and the steps were referred to the HTRF KinEASE-TK kit. Then 10 μL of TK Ab-Cryptate and Sa-XL665 detection system was added, mixed, and incubated at 25°C for 60 min. The readings were read on a BioTek microplate reader (Synergy Neo2), and the inhibition rate of the enzyme by compounds at different concentrations was calculated. The data were analyzed using GraphPad Prism 7.0 software, and the dose-effect curve was fitted using nonlinear curve regression, and the IC was calculated from this. 50 value.

[0611] The compounds of the present invention were tested in the above-mentioned kinase inhibition experiment and found to have potent activity against EGFR del19, EGFR L858R, EGFR del19 T790M, EGFR L858R T790M, EGFR del19 T790M C797S, EGFRL858R T790M C797S kinases while retaining activity against EGFR WT.

[0612] (2) Testing of the growth inhibitory activity of wild-type EGFR and mutant EGFR cells

[0613] The inhibitory effects of the exemplified compounds on a total of 12 cell activities were detected, including Ba / F3 parental, Ba / F3 EGFR WT, Ba / F3 EGFR del19, Ba / F3 EGFRL858R, Ba / F3 EGFR del19 T790M, Ba / F3 EGFR L858R T790M, Ba / F3 EGFR del19 T790MC797S, Ba / F3 EGFR L858R T790M C797S, A431 (human skin squamous cell carcinoma cell EGFR WT), HCC827 (human non-small cell lung cancer NSCLC, EGFR del19), NCI-H1975 (human lung adenocarcinoma cell line EGFR L858R T790M) and NCI-H1975 L858R T790M C797S (human lung adenocarcinoma cell line EGFR L858R T790M C797S).

[0614] Consumables and reagents: Fetal bovine serum FBS (GIBCO, catalog number 10099141), CellTiter- Luminescent Cell Viability Assay (Promega, catalog number G7572), 96-well clear flat-bottom black wall plate ( Catalog No. 3603).

[0615] Experimental methods:

[0616] Cell culture and seeding:

[0617] 1. Harvest cells in the logarithmic growth phase and count the cells using a platelet counter. Detect cell viability using the trypan blue exclusion method to ensure that the cell viability is above 90%;

[0618] 2. Adjust the cell concentration to 500-5000 cells / well; add 100 μL of cell suspension to each 96-well plate;

[0619] 3. Culture the cells in the 96-well plate overnight at 37°C, 5% CO2, and 95% humidity;

[0620] 4. Spread another 96-well plate, set up 3-4 duplicate wells with cells of the same concentration, 3-4 duplicate wells with culture medium as blank control, measure T0 plate, and read the plate when adding drugs the next day. The values ​​measured in the wells with cells and the wells without cells are LumT0 and LumB0 respectively.

[0621] Drug dilution and dosing:

[0622] 1. Prepare 3-fold drug solution, with the highest concentration of 10 μM, 9 concentrations, and gradients of 3 μM, 1 μM, 0.3 μM, 0.1 μM, etc. Add 50 μL of drug solution to each well of the 96-well plate inoculated with cells, and set up three replicate wells for each drug concentration; 0.5% DMSO is the solvent control. The well without cells is the blank control.

[0623] 2. If the activity is high, lower the highest concentration to 3μM or 1μM or 0.3μM or 0.1μM, and take 9 concentrations down to make the IC 50 Within a reasonable range of the selected concentration interval.

[0624] 3. The cells in the 96-well plate with the drug added were placed in 37°C, 5% CO2, and 95% humidity for 72 hours, and then CTG analysis was performed. The values ​​measured in the wells with cells and the wells without cells were LumT and LumB, respectively.

[0625] Endpoint plate reading:

[0626] 1. Thaw CTG reagent to room temperature for 30 minutes;

[0627] 2. Add an equal volume (40 μL) of CTG reagent to each well;

[0628] 3. Shake on an orbital shaker for 10 minutes to lyse the cells;

[0629] 4. Place the cell plate at room temperature for 30 minutes to stabilize the cold light signal;

[0630] 5. Read the luminescence value.

[0631] Data processing

[0632] The data were analyzed using GraphPad Prism 7.0 software, and nonlinear S-curve regression was used to fit the data to obtain the dose-effect curve, from which the IC 50 value.

[0633] Cell growth inhibition rate (%) = 1-(Lum test drug-Lum solvent control) / (Lum cell control-Lum solvent control)×100%.

[0634] The data were analyzed using GraphPad Prism 7.0 software, and nonlinear S-curve regression was used to fit the data to obtain the dose-effect curve, from which the IC 50 The experimental results show that: compared with the non-deuterated compound (E)-1 1 ,2 6 ,7-Trimethyl-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3-Dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-3-one (defined as compound ), the racemic compound of the present invention exhibits lower inhibitory activity against Ba / F3 EGFR WT and A431 wild-type cells, which are associated with drug side effects, and exhibits higher inhibitory activity against Ba / F3 EGFR del19, Ba / F3 EGFR L858R, Ba / F3 EGFR del19 T790M, Ba / F3 EGFRL858R T790M, Ba / F3 EGFR del19 T790M C797S and Ba / F3 EGFR L858R T790M C797S, HCC827, NCI-H1975 and NCI-H1975 L858R T790M C797S mutant cells;

[0635] With the non-deuterated compound (R,E)-1 1 ,2 6 ,7-Trimethyl-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)- 2 ,5 3 -Dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-3-one (i.e., BI-4020, defined as compound ), the R-configuration compound of the present invention exhibits lower inhibitory activity against Ba / F3 EGFR WT and A431 wild-type cells, which are associated with drug side effects, and exhibits higher inhibitory activity against Ba / F3 EGFRdel19, Ba / F3 EGFR L858R, Ba / F3 EGFR del19 T790M, Ba / F3 EGFR L858R T790M, Ba / F3EGFR del19 T790M C797S and Ba / F3 EGFR L858R T790M C797S, HCC827, NCI-H1975 and NCI-H1975 L858R T790M C797S mutant cells;

[0636] With the non-deuterated compound (S,E)-1 1 ,2 6 ,7-Trimethyl-5 6 -((4-methylpiperazin-1-yl)methyl)-5-((4-methylpiperazin-1-yl)methyl)-2 ,5 3 -Dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazo-2(2,4)-pyrido-1(4,5)-pyrazolocyclododecaphen-3-one (defined as compound ), the S-configuration compound of the present invention exhibits lower inhibitory activity against Ba / F3EGFR WT and A431 wild-type cells that are associated with drug side effects, but exhibits higher inhibitory activity against Ba / F3 EGFR del19, Ba / F3 EGFRL858R, Ba / F3 EGFR del19 T790M, Ba / F3 EGFR L858R T790M, Ba / F3 EGFR del19 T790MC797S and Ba / F3 EGFR L858R T790M C797S, HCC827, NCI-H1975 and NCI-H1975 L858R T790MC797S mutant cells.

[0637] Therefore, compared with the non-deuterated compounds, the compounds of the present invention exhibit higher activity and selectivity against EGFR del 19 / L858R variants with or without T790M and / or C797S mutations. More importantly, the compounds of the present invention can significantly inhibit EGFR with C797S mutation while retaining activity against wild-type EGFR, with excellent selectivity (e.g., IC of Ba / F3 EGFR WT cells: 50 Divide by IC of Ba / F3 EGFR L858R T790M C797S 50 For example, the compounds T-3-R and T-4-R of the present invention have a selectivity of more than 1000 for Ba / F3 EGFR L858R T790M C797S relative to Ba / F3 EGFR WT. The results of representative example compounds are summarized in Tables 1 and 2 below.

[0638] Table 1:

[0639]

[0640] Table 2:

[0641]

[0642]

[0643] (3) Metabolic stability evaluation

[0644] Metabolic stability is generally used to describe the speed and extent of a compound's metabolism, and is one of the main factors affecting pharmacokinetic properties. Many compounds are substrates for CYP450 enzymes and other drug-metabolizing enzymes, and liver microsomes are a system rich in CYP450. The purpose of this experiment is to study the in vitro metabolic stability of the compound by incubating it with human and SD rat liver microsomes and using LC-MS / MS to detect the remaining proportion of the compound.

[0645] ① Preparation of solution

[0646] Phosphate buffered saline (PBS): Mix 150 mL of pre-prepared KH2PO4 (0.5 M) solution and 700 mL of K2HPO4 (0.5 M) solution, and adjust the pH value of the mixture to 7.4 with K2HPO4 (0.5 M) solution to prepare 5-fold PBS, and store at 4°C for later use. Dilute 5-fold with ultrapure water before use, and add 3.3 mM magnesium chloride to obtain phosphate buffered saline (PBS) (100 mM).

[0647] NADPH regeneration system solution: Use 5 mL of PBS to prepare an NADPH solution containing 6.5 mM NADP, 16.5 mM G-6-P, and 3 U / mL G-6-PD.

[0648] Internal standard stop solution: Prepare 50 ng / mL propranolol hydrochloride and 200 ng / mL tolbutamide in acetonitrile as internal standard working solution.

[0649] Human liver microsome solution: Take 0.31 mL of human liver microsomes (25 mg / mL) and add them to 0.961 mL of PBS (pH 7.4) and mix well to obtain a human liver microsome dilution solution with a protein concentration of 0.625 mg / mL.

[0650] SD rat liver microsome solution: Take 0.31 mL of SD rat liver microsome (25 mg / mL) and add it to 0.961 mL of PBS (pH 7.4) and mix well to obtain a SD rat liver microsome dilution solution with a protein concentration of 0.625 mg / mL.

[0651] Sample working solution: The compound of the present invention and non-deuterated compound powder, positive control dextromethorphan powder and omeprazole powder were prepared with DMSO to 10 mM as sample stock solution, and then diluted with 70% acetonitrile-water to obtain 0.25 mM sample working solution.

[0652] ②Sample incubation

[0653] 398 μL of human liver microsome dilution was added to a 96-well incubation plate (N=2), and 2 μL of 0.25 mM test compound and dextromethorphan were added respectively and mixed.

[0654] 398 μL of SD rat liver microsome dilution was added to a 96-well incubation plate (N=2), and 2 μL of 0.25 mM test compound and omeprazole were added respectively and mixed.

[0655] Add 300 μL of pre-cooled stop solution to each well of a 96-well deep-well plate and place on ice to serve as a stop plate.

[0656] Place the 96-well incubation plate and NADPH regeneration system in a 37°C water bath, shake at 100 rpm, and pre-incubate for 5 minutes. Take out 80 μL of incubation solution from each well of the incubation plate and add it to the termination plate, mix well, and add 20 μL of NADPH regeneration system solution as the 0min sample. Add 80 μL of NADPH regeneration system solution to each well of the incubation plate, start the reaction, and start timing. The reaction concentration of the test compound is 1 μM, and the protein concentration is 0.5 mg / mL.

[0657] At 10, 30, and 90 min of reaction, 100 μL of the reaction solution was taken and added to the stop plate, and vortexed for 3 min to terminate the reaction.

[0658] The stop plate was centrifuged at 5000 rpm and 4°C for 15 min. 200 μL of supernatant was taken into a 96-well plate pre-added with 200 μL of ultrapure water, mixed well, and sampled by LC-MS / MS, injecting 10 uL.

[0659] ③Sample analysis method

[0660] In this experiment, the LC-MS / MS system was used to detect the peak areas of the test compound, dextromethorphan, omeprazole and internal standard, and the peak area ratio of the compound to the internal standard was calculated.

[0661] ④Data processing

[0662] The peak areas of the samples and internal standards were obtained by mass spectrometer and Analyst software. The residual amount of the compound (R%) and time were plotted using the single exponential degradation model of Graphpad prism7.0 software to obtain the substrate elimination rate constant K.

[0663] Ct / C0=exp(-K*t)

[0664] The half-life T is calculated according to the following formula: 1 / 2 and intrinsic clearance CL int , where V / M is equal to 1 / C(protein).

[0665] t 1 / 2 (min); CL int (μL / min / mg).

[0666] Experimental results: The compounds of the present invention and their non-deuterated compounds were tested and compared to evaluate their metabolic stability in human and SD rat liver microsomes. Compared with the non-deuterated compounds, the compounds of the present invention have a longer half-life T 1 / 2 and lower clearance CL int The results of representative example compounds are summarized in Table 3.

[0667] Table 3:

[0668]

[0669]

[0670] (4) Pharmacokinetic experiments in rats

[0671] Six male Sprague-Dawley rats, 7-8 weeks old, weighing about 210 g, were divided into two groups, 3 rats in each group, and a single dose of the compound (10 mg / kg orally) was administered intravenously or orally to compare the pharmacokinetic differences.

[0672] Rats were fed with standard diet and given water. Fasting began 16 hours before the experiment. Drugs were dissolved with PEG400 and dimethyl sulfoxide. Blood was collected from the orbit at 0.083 hours, 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after administration.

[0673] The rats were briefly anesthetized by inhalation of ether, and 300 μL of blood was collected from the orbits into test tubes. The test tubes contained 30 μL of 1% heparin saline solution. Before use, the test tubes were dried at 60°C overnight. After the last time point of blood sampling, the rats were killed under ether anesthesia.

[0674] After blood sample collection, gently invert the test tube at least 5 times to ensure sufficient mixing and place on ice. The blood sample is centrifuged at 4°C 5000rpm for 5 minutes to separate plasma from red blood cells. Use a pipette to aspirate 100μL of plasma into a clean plastic centrifuge tube and mark the name of the compound and time point. The plasma is stored at -80°C before analysis. The concentration of the compound of the present invention in plasma is determined by LC-MS / MS. Pharmacokinetic parameters are calculated based on the blood drug concentration of each animal at different time points.

[0675] Experiments show that the compound of the present invention has better pharmacokinetic properties in animals, and therefore has better pharmacodynamics and therapeutic effects.

[0676] The above contents are further detailed descriptions of the present invention in combination with specific preferred embodiments, and it cannot be determined that the specific implementation of the present invention is limited to these descriptions. For ordinary technicians in the technical field to which the present invention belongs, several simple deductions or substitutions can be made without departing from the concept of the present invention, which should be regarded as falling within the protection scope of the present invention.

[0677] In summary, the present invention relates to the following technical solutions:

[0678] 1. A compound of formula (I), or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof:

[0679]

[0680] in,

[0681] Y1, Y2, Y3, Y4, Y5 and Y6 are each independently selected from hydrogen, deuterium or halogen;

[0682] R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0683] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0684] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0685] Provided that the above compound contains at least one deuterium atom.

[0686] 2. The compound according to technical solution 1, which is a compound of formula (IA):

[0687]

[0688] Among them, Y1, Y2, Y3, Y4, Y5, Y6, R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16, R 17 , R 18 , R 19 , X1, X2, X3 and X4 are as defined in claim 1;

[0689] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0690] 3. The compound according to technical solution 1, which is a compound of formula (IB):

[0691]

[0692] Among them, Y1, Y2, Y3, Y4, Y5, Y6, R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2, X3 and X4 are as defined in claim 1;

[0693] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0694] 4. The compound according to any one of technical solutions 1 to 3, wherein X1 is CD3.

[0695] 5. A compound according to any one of technical solutions 1 to 4, wherein X2 is CD3.

[0696] 6. A compound according to any one of technical solutions 1 to 5, wherein X3 is CD3.

[0697] 7. A compound according to any one of technical solutions 1 to 6, wherein X4 is CD3.

[0698] 8. The compound according to technical solution 1, which is a compound of formula (II):

[0699]

[0700] in,

[0701] R 10 , R 11 , R 12 , R 13 , R 14 , R 15, R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0702] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0703] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0704] Provided that the above compound contains at least one deuterium atom;

[0705] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0706] 9. The compound according to technical solution 8, which is a compound of formula (IIA):

[0707]

[0708]

[0709] Among them, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2, X3 and X4 are as defined in claim 8;

[0710] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0711] 10. The compound according to technical solution 8, which is a compound of formula (IIB):

[0712]

[0713] Among them, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2, X3 and X4 are as defined in claim 8;

[0714] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0715] 11. A compound according to any one of technical solutions 8 to 10, wherein X1 is CD3.

[0716] 12. A compound according to any one of technical solutions 8-11, wherein X2 is CD3.

[0717] 13. A compound according to any one of technical solutions 8-12, wherein X3 is CD3.

[0718] 14. A compound according to any one of technical solutions 8-13, wherein X4 is CD3.

[0719] 15. A compound according to any one of technical solutions 8-14, wherein R 10 and R 11 It's deuterium.

[0720] 16. A compound according to any one of technical solutions 8-15, wherein R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 It's deuterium.

[0721] 17. The compound according to technical solution 1, which is a compound of formula (III):

[0722]

[0723] in,

[0724] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0725] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0726] Provided that the above compound contains at least one deuterium atom;

[0727] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0728] 18. The compound according to technical solution 17, which is a compound of formula (IIIA):

[0729]

[0730] Wherein, X1, X2, X3 and X4 are as defined in claim 17;

[0731] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0732] 19. The compound according to technical solution 17, which is a compound of formula (IIIB):

[0733]

[0734] Wherein, X1, X2, X3 and X4 are as defined in claim 17;

[0735] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0736] 20. A compound according to any one of technical solutions 17-19, wherein X1 is CD3.

[0737] 21. A compound according to any one of technical solutions 17-20, wherein X2 is CD3.

[0738] 22. A compound according to any one of technical solutions 17-21, wherein X3 is CD3.

[0739] 23. A compound according to any one of technical solutions 17-22, wherein X4 is CD3.

[0740] 24. The compound according to technical solution 1, which is a compound of formula (IV):

[0741]

[0742] in,

[0743] R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 are each independently selected from hydrogen or deuterium;

[0744] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0745] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0746] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0747] 25. The compound according to technical solution 24, which is a compound of formula (IVA):

[0748]

[0749] Among them, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2, X3 and X4 are as defined in claim 24;

[0750] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0751] 26. The compound according to technical solution 24, which is a compound of formula (IVB):

[0752]

[0753] Among them, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , X1, X2, X3 and X4 are as defined in claim 24;

[0754] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0755] 27. A compound according to any one of technical solutions 24-26, wherein X1 is CD3.

[0756] 28. A compound according to any one of technical solutions 24-27, wherein X2 is CD3.

[0757] 29. A compound according to any one of technical solutions 24-28, wherein X3 is CD3.

[0758] 30. A compound according to any one of technical solutions 24-29, wherein X4 is CD3.

[0759] 31. A compound according to any one of technical solutions 24-30, wherein R 10 and R 11 It's deuterium.

[0760] 32. A compound according to any one of technical solutions 24-31, wherein R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 It's deuterium.

[0761] 33. The compound according to technical solution 1, which is a compound of formula (V):

[0762]

[0763] in,

[0764] X1, X2 and X3 are each independently selected from CH3, CD3, CHD2 or CH2D;

[0765] X4 is selected from H, CH3, CD3, CHD2 or CH2D;

[0766] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0767] 34. The compound according to technical solution 33, which is a compound of formula (VA):

[0768]

[0769] Wherein, X1, X2, X3 and X4 are as defined in claim 33;

[0770] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0771] 35. The compound according to technical solution 33, which is a compound of formula (VB):

[0772]

[0773] Wherein, X1, X2, X3 and X4 are as defined in claim 33;

[0774] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0775] 36. A compound according to any one of technical solutions 33-35, wherein X1 is CD3.

[0776] 37. A compound according to any one of technical solutions 33-36, wherein X2 is CD3.

[0777] 38. A compound according to any one of technical solutions 33-37, wherein X3 is CD3.

[0778] 39. A compound according to any one of technical solutions 33-38, wherein X4 is CD3.

[0779] 40. The compound according to technical solution 1, which is selected from the following compounds:

[0780]

[0781]

[0782]

[0783]

[0784]

[0785]

[0786]

[0787]

[0788]

[0789]

[0790]

[0791]

[0792] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0793] 41. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound according to any one of technical solutions 1 to 40, or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0794] 42. Use of the compound according to any one of technical solutions 1 to 40, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, or the pharmaceutical composition according to technical solution 41 in the preparation of a drug for treating and / or preventing a disease associated with or mediated by mutant EGFR;

[0795] 43. The use according to technical solution 42, wherein the mutant EGFR is selected from EGFR del19, EGFR L858R, EGFR del19 T790M, EGFR L858R T790M, EGFR del19 T790M C797X (X=S, G, N), EGFR L858R T790M C797X (X=S, G, N), EGFR del19 T790M L792X (X=F, H, Y) or EGFR L858RT790M L792X (X=F, H, Y).

[0796] 44. The use according to technical solution 42, wherein the mutant EGFR is selected from EGFR del19, EGFR L858R, EGFR del19 T790M, EGFR L858R T790M, EGFR del19 T790M C797S or EGFR L858RT790M C797S.

[0797] 45. The use according to technical solution 42, wherein the disease associated with or mediated by the mutant EGFR is cancer.

[0798] 46. ​​The use according to technical solution 45, wherein the cancer is lung cancer, brain cancer, colorectal cancer, bladder cancer, urothelial carcinoma, breast cancer, prostate cancer, ovarian cancer, head and neck cancer, pancreatic cancer, gastric cancer, mesothelioma, and their metastases.

[0799] 47. The use according to technical solution 46, wherein the metastasis is brain metastasis.

[0800] 48. The use according to technical solution 46, wherein the lung cancer is locally advanced or metastatic NSCLC, NSCLC adenocarcinoma, NSCLC with squamous histology, and NSCLC with non-squamous histology.

[0801] 49. The use according to technical solution 48, wherein the lung cancer is NSCLC adenocarcinoma.

Claims

1. A compound of formula (III), or a pharmaceutically acceptable salt thereof: in, X 1 , X 2 and X 3 Each independently selected from CH 3 or CD 3 ; X 4 Selected from CH 3 or CD 3 ; The additional condition is that the above compound contains at least three deuterium atoms and X 4 For CD 3 When X 1 , X 2 and X 3 Not at the same time CH 3 ; The deuterium isotope content of each deuterated position is at least greater than 70%.

2. The compound according to claim 1, which is a compound of formula (IIIA): in, X 1 , X 2 , X 3 and X 4 As defined in claim 1; or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1, which is a compound of formula (IIIB): in, X 1 , X 2 , X 3 and X 4 As defined in claim 1; or a pharmaceutically acceptable salt thereof.

4. A compound according to any one of claims 1 to 3, in, X 1 For CD 3 .

5. A compound according to any one of claims 1 to 3, in, X 2 For CD 3 .

6. The compound according to claim 4, in, X 2 For CD 3 .

7. A compound according to any one of claims 1 to 3, in, X 3 For CD 3 .

8. The compound according to claim 4, in, X 3 For CD 3 .

9. The compound according to claim 5, in, X 3 For CD 3 .

10. The compound according to claim 6, in, X 3 For CD 3 .

11. A compound according to any one of claims 1 to 3, in, X 4 For CD 3 .

12. The compound according to claim 4, in, X 4 For CD 3 .

13. The compound according to claim 5, in, X 4 For CD 3 .

14. The compound according to claim 6, in, X 4 For CD 3 .

15. The compound according to claim 7, in, X 4 For CD 3 .

16. The compound according to claim 8, in, X 4 For CD 3 .

17. The compound according to claim 9, in, X 4 For CD 3 .

18. The compound according to claim 10, in, X 4 For CD 3 .

19. The compound according to claim 1, which is selected from the following compounds: or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof.

21. Use of the compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 20, in the preparation of a medicament for treating and / or preventing a disease associated with or mediated by mutant EGFR.

22. The use according to claim 21, wherein the mutant EGFR is selected from EGFR del19, EGFR L858R, EGFR del19 T790M, EGFR L858R T790M, EGFR del19 T790M C797S, EGFR del19 T790MC797G, EGFR del19 T790M C797N, EGFR L858R T790M C797S, EGFR L858R T790M C797G, EGFR L858R T790M C797N, EGFR del19 T790M L792F, EGFR del19 T790M L792H, EGFRdel19 T790M L792Y, EGFR L858R T790M L792F, EGFR L858R T790M L792H or EGFR L858RT790M L792Y.

23. The use according to claim 21, wherein the mutant EGFR is selected from EGFR del19, EGFR L858R, EGFR del19 T790M, EGFR L858R T790M, EGFR del19 T790M C797S or EGFR L858R T790MC797S.

24. The use according to claim 21, wherein the disease associated with or mediated by the mutant EGFR is cancer.

25. The use according to claim 24, wherein the cancer is lung cancer, brain cancer, colorectal cancer, bladder cancer, urothelial cancer, breast cancer, prostate cancer, ovarian cancer, head and neck cancer, pancreatic cancer, gastric cancer, mesothelioma, and metastases thereof.

26. The use according to claim 25, wherein the metastasis is brain metastasis.

27. The use according to claim 25, wherein the lung cancer is locally advanced or metastatic NSCLC, NSCLC adenocarcinoma, NSCLC with squamous histology and NSCLC with non-squamous histology.

28. The use according to claim 27, wherein the lung cancer is NSCLC adenocarcinoma.